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Optogenetics has demonstrated great promise as a direct neuromodulatory tool for 
halting seizure activity in various animal models of epilepsy. However, light delivery into 
the brain is still a major practical challenge that needs to be addressed before future 
clinical translation is feasible. Not only does light delivery into the brain require 
surgically implanted hardware that can be both invasive and restrictive, but it is also 
difficult to illuminate large or complicated structures in the brain due to light scatter and 
attenuation. We have bypassed the challenges of external light delivery by directly 
coupling a bioluminescent light source (a genetically encoded Renilla luciferase) to an 
inhibitory opsin (Natronomonas halorhodopsin) as a single fusion protein, which we term 
an inhibitory luminopsin (iLMO). 
iLMOs were developed, tested, and characterized in vitro and in vivo using 
intracellular recordings, multielectrode arrays, and behavioral testing. iLMO2 was shown 
to generate hyperpolarizing outward currents in response to both external light and 
luciferase substrate, which was sufficient to suppress action potential firing and 
synchronous bursting activity in vitro. iLMO2 was further shown to suppress single-unit 
firing rate and local field potentials in the hippocampus of anesthetized and awake 
animals. Finally, expression of iLMO was scaled up to multiple structures of the basal 
ganglia to modulate rotational behavior of freely moving animals in a hardware-
independent fashion. iLMO2 was further utilized to acutely suppress focal epileptic 
discharges induced by intracerebral injection of bicuculline and generalized seizures 
resulting from system administration of pentylenetetrazol. 
 xii 
Several calcium-dependent luciferases have also been utilized as a means to 
report neural activity with bioluminescence. These have been coupled to inhibitory opsins 
as responsive luminopsins (rLMOs) that are capable of responding to neural activity. 
Inhibitory luminopsins have enabled the possibility of optogenetic inhibition of 
neural activity in a non-invasive and hardware-independent fashion. This work increases 
the versatility, scalability, and practicality of utilizing optogenetic approaches for halting 











 The human brain is comprised of billions of cells talking to one another in a 
complex network consisting of trillions of connections. Each cell is like a different 
instrument contributing to a vast symphony of activity that is intricately coordinated 
together to dictate the complex behaviors we see and exhibit every day. When this 
activity is not coordinated, it can lead to pathological conditions such as epilepsy.  
 To understand how the brain works and eventually correct the abnormal activity 
seen in diseases such as epilepsy, we need tools that can isolate each ‘instrument’ and 
measure its contribution to the entire behavior. For example, if the brass section is 
playing too fast or the cellos are joining in too loudly, we need to be able to selectively 
slow down brass instruments and quiet down the cellos in order to maintain the harmonic 
balance of the symphony. Our laboratory has been interested in using a revolutionary 
technique called optogenetics, which allows scientists to selectively modulate the activity 
of neurons in a cell-type specific manner with light. We aim to utilize this precise tool to 
correct the abnormal ‘cacophonous’ activity seen in epilepsy. 
 This introductory chapter will provide a brief overview of existing treatment 
options for patients with epilepsy as a framework for describing optogenetics, a powerful 
tool that has shown great potential as a future neuromodulatory therapy. I will then 
review the current progress made with optogenetic approaches to treat epilepsy and then 
describe the limitations that currently impede effective clinical translation of these 
techniques, which is the main challenge that this thesis aims to address. 
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1.1 Epilepsy is a disorder of abnormal neuronal activity  
Epilepsy currently affects 3 million people in the U.S. and 65 million people worldwide, 
or roughly 1% of the population, accounting for a significant worldwide health burden. 
About 150,000 patients in the U.S. and 2.4 million worldwide are diagnosed with 
epilepsy every year. Annual epilepsy related medical expenditures are close to $10 billion 
annually in the U.S. alone1 and up to $4748 in direct annual costs per patient in other 
countries2. 
 Epilepsy is a disease characterized by aberrant neural activity in the brain that 
ultimately leads to recurrent and spontaneous seizures. Seizures can manifest in a variety 
of ways due to multiple etiologies and their onsets are characteristically unpredictable. 
Epilepsy is therefore a very debilitating disease for both patients and their affected 
families because performance of daily life activities is often impaired, injuries and even 
death are not uncommon, cognitive decline is frequent, and socioeconomic decline 
prevalent. In fact, epilepsy was responsible for approximately 20.6 million disability-
adjusted life years lost in 20123.  
 Pharmacotherapy is generally the first treatment choice option for patients with 
epilepsy. Fortunately, most patients are able to control their seizures with anti-epileptic 
drugs. However, these drugs are generally required for the lifetime of the patient and are 
also commonly associated with side effects that are poorly tolerated in some patients4. 
Moreover, 30% of patients with epilepsy do not become seizure free with anti-epileptic 
drugs5. These drug-resistant patients are generally limited to two other treatment options: 
resective surgery or neurostimulation.  
 Candidates who are deemed eligible and undergo resective surgery of the 
epileptic tissue are generally able to achieve complete seizure freedom 60-70% of the 
time6. As with any surgical procedure, there is risk for adverse events associated with 
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intracranial EEG monitoring (if needed), surgery, and recovery. These patients are also at 
risk for neurological deficits such as memory, speech and motor impairments, especially 
if the area of resection lies in eloquent brain areas. Because of these significant risks and 
stringent inclusion criteria, and for other reasons such as risk-aversion and lack of 
referrals or access to care, only about 3000 patients actually receive surgery each year7. 
 Neuromodulatory approaches to correcting abnormal brain activity have shown 
great promise in reducing seizures in patients with intractable epilepsy and the various 
approaches used in the past are illustrated in Figure 1.1.1a. The most successful therapies 
include vagus nerve stimulation8–10, stimulation of the anterior nucleus of the thalamus 
(SANTE) 11,12, and responsive neurostimulation (RNS) of epileptic foci 13,14. Clinical 
trials using these devices have demonstrated that 56-68% of patients were able to reduce 
their seizure frequency by more than 50% at their last visit (the average reduction of 
seizures in these patients was 48-76%)15. Although electrical stimulation allows more 
targeted and reversible therapy to the brain compared to pharmacotherapy or surgical 
resection, it is still a challenge to specifically and effectively target only pathological 
circuits while leaving healthy tissue undisturbed (Figure 1.1.2a). This is primarily due to 
the fact that the effects of electrical stimulation on the surrounding tissue are highly 
dependent on patient-specific neuroanatomy (e.g. it is remains difficult to effectively 
reach seizure onset zones located in deep sulci) and parameters of stimulation, which can 
be hard to predict. Given the potential side effects, suboptimal response rates, and 





Figure 1.1.1. Neuromodulation targets for epilepsy. (A) Electrical stimulation 
targets used in human patients with epilepsy. Reprinted from Fisher, R. S. & Velasco, 
A. L. (2014). (B) Optogenetic stimulation targets previously used in rodents. 
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1.2 Optogenetics: a revolutionary method to control neuronal activity with light. 
Optogenetics offers an unprecedented ability to alter neuronal activity with very high 
spatial and temporal accuracy. By utilizing cell-specific expression of light-sensitive ion 
channels and pumps (opsins) in the brain, scientists can selectively activate (Figure 
1.1.2b) or inhibit (Figure 1.1.2c) specific cell populations in the context of complex 
neural circuitry. This unprecedented degree of control of cell-type specific physiology 
has proven to be an invaluable research tool enabling neuroscientists to study a wide 
variety of topics such as brain circuitry, learning, movement, and behavior like never 
before. 
 Two of the most widely used opsins in neuroscience research are 
channelrhodopsin (ChR) and halorhodopsin (NpHR). ChR is a non-selective cation 
channel that becomes activated in the presence of blue light (Figure 1.2.1a). Blue light is 
therefore capable of depolarizing the membrane potential of neurons expressing ChR and 
driving action potential firing16. In contrast, NpHR is a chloride pump that is activated in 
the presence of yellow light17. When neurons expressing NpHR are illuminated by yellow 
light, chloride is transported into the cytosol, hyperpolarizing the membrane potential and 
 
Figure 1.1.2. Optogenetic vs. electrical stimulation approaches to 
neuromodulation. (A) The effects of electrical stimulation is highly dependent on 
stimulation parameters and acts nonspecifically on cells around the stimulating 
electrode. The effects of optogenetic excitation (B) or inhibition (C) can be cell-type 
specific. Figure reprinted from Nature Methods 8, 26–29 (2011). 
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decreasing the likelihood of action potential firing (Figure 1.2.1b). Both of these opsins 
have been utilized for seizure control in the studies outlined in this chapter. 
 There are several methods of expressing opsins in the rodent brain, each with 
advantages and disadvantages. One common method utilizes viral vectors, which allow 
for efficient long-term expression of transgenes. Viral vectors encoding opsin genes are 
produced in vitro and are subsequently injected into the brain where they can transduce 
target cells. Cell-type specific expression of opsins can be achieved by utilizing an 
appropriate promoter driving transgene expression. Another method used to achieve cell-
type specific expression of opsins uses Cre-recombinase driver animals, in which floxed 
or double-inverted vectors containing opsin genes can be specifically expressed in Cre-
recombinase positive cells, driven by cell-specific promotors18–20. Cre-driver mouse lines 
are widely available, and rat lines are increasingly being produced as well. Various 





Figure 1.2.1. Channelrhodopsin and Halorhodopsin. (A) Channelrhodopsin 
(ChR2) is a cation channel that opens in the presence of blue (470nm) light. (B) 
Halorhodopsin (NpHR) is a chloride pump that activates in the presence of yellow 
(589nm) light. Figure modified from Zhang, F. et al. Nat. Protoc. 5, 439–56 (2010). 
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1.3 Optogenetic approaches to treating epilepsy. 
 With the ability to selectively excite or inhibit neuronal activity in cell type-
specific fashion with optogenetics, three major approaches have been taken to interrupt 
seizure activity in the rodent: nonspecific inhibition of neurons, inhibiting excitatory (e.g. 
glutamatergic) neurons, and exciting inhibitory (e.g. GABAergic) neurons. The structures 
that have been targeted and the experimental approaches utilized are illustrated in Figure 
1.1.1b and Figure 1.3.1, respectively, and summarized in Table 1.3.  
 
Nonspecific inhibition of neurons 
 Since seizures are generally thought to manifest from overexcitability of 
pathological circuits, researchers have naturally tried to decrease the excitability of these 
circuits using NpHR. Berglind et al.21 utilized an adeno-associated virus (AAV) encoding 
enhanced NpHR (eNpHR3.0) under control of the human synapsin promoter (hSyn) to 
express NpHR in ubiquitously in neurons of the mouse hippocampus. Epileptiform 
bursting was induced in these animals by compromising inhibitory drive with acute 
injection of bicuculline into the hippocampus. Upon illumination with yellow light, the 
authors were able to decrease epileptiform burst rate by 17%. Although the reduction in 
burst rate was significant, the rather modest decrease in epileptiform bursts was attributed 
to the diffusion of bicuculline being too widespread compared to the area of optogenetic 
inhibition.  
 It is often difficult to interpret effects of optogenetic manipulation if opsin 
expression is found in multiple cell types in the area of illumination (e.g. with a CMV, 
EF1α, or hSyn promoter). For example, the hSyn promoter drives expression of NpHR 
not only in excitatory pyramidal cells, but also in interneurons, the inhibition of which 
could potentially offset the inhibitory effects of silencing principal cells as they become 
disinhibited by decreased inputs from interneurons. Although GABAA transmission was 
blocked with bicuculline in these experiments, there still may have been other inhibitory 
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circuits that were not affected by bicuculline (such as GABAB expressing or glycinergic 
neurons) that could have been subsequently turned off by optogenetic inhibition. 
 
Inhibition of principal glutamatergic neurons 
Tonnesen et al.22 first demonstrated that specific inhibition of principal cortical neurons 
via a lentivirus carrying NpHR under control of the calcium/calmodulin-dependent kinase 
II isoform α (CaMKIIα) promoter was sufficient in reducing epileptiform activity in 
hippocampal organotypic brain slices. The same virus was used in a chronic tetanus toxin 
model of epilepsy in rats by Wykes et al 23, where NpHR activation in the motor cortex of 
awake animals was shown to attenuate epileptic activity induced by tetanus toxin. In this 
study, rats were photostimulated 7-10 days after co-injection of tetanus toxin and a 
CaMKIIα-NpHR2.0 lentivirus in the motor cortex. Although photostimulation was able 
to significantly reduce epileptic activity in the electroencephalogram (EEG), it was not 
sufficient to completely prevent all epileptic EEG events or produce any behavioral 
effects.This could be partially attributed to suboptimal expression levels of NpHR in the 
brain. For example, the copy number of NpHR delivered to neurons in the brain may be 
relatively small due to the fact that it is often difficult to obtain high-titer lentivirus 
compared to adeno-associated viral vectors (AAV). Furthermore, trafficking of NpHR to 
the cell membrane has been shown to be rather inefficient and may thus lead to 
suboptimal hyperpolarization of membrane potential upon photoactivation. Membrane 
trafficking of NpHR has been subsequently improved with addition of trafficking and 
endoplasmic reticulum-export sequences to eNphR3.0, improving NpHR photocurrent 
dramatically24.  
 Sukhotinsky et al. 25 utilized this improved eNphR3.0 for delaying seizure activity 
in an acute model of epilepsy in rats. In this study, an AAV encoding CaMKIIα-
eNphR3.0 was injected into the hippocampus. Photoactivation (both continuous and 
pulsed illumination) in these animals was able to significantly delay the onset of status 
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epilepticus (by 6 minutes) following systemic pilocarpine injection in awake behaving 
animals. Although both electrographic and behavioral manifestations of seizures were 
able to be delayed in these animals, they were not completely abolished. The modest 
scale of seizure attenuation was attributed to the fact that the seizure model they used was 
not focal, resulting in a large number of potentially epileptogenic neurons residing 
outside the range of light delivery and expression of opsin. 
 
Excitation of interneurons 
A high frequency stimulation approach (akin to DBS,) to optogenetic stimulation was 
taken by Chiang et al.26 50-Hz photostimulation of the hippocampus of transgenic mice 
expressing ChR2 under control of the Thy1 promoter was able to suppress seizures 
evoked by intracerebral injection of 4-aminopyridine by 82.4%. Although the Thy1 
promoter is non-specifically expressed in neurons of the brain, the authors found that 
ChR2 expression was mostly localized to GABAergic interneurons in the hippocampus, 
suggesting that seizure suppression was achieved by enhancing inhibitory GABAergic 
inputs to overexcited circuits in the hippocampus. 
 Targeting interneurons with ChR2 seems especially appropriate for epilepsy 
models that result from a loss of inhibitory activity. The advantage of this approach is 
that GABAergic interneurons widely innervate multiple pyramidal cells in the 
hippocampus27,28 and could thus exert very strong effects on the epileptic network. 
However, GABAergic interneurons have also been directly implicated in synchronizing 
epileptic activity29–31 and conceivably could potentiate seizure activity following 
photoactivation. Stimulation parameters must therefore be carefully determined to ensure 
that proper inhibitory drive is delivered to the circuit in question. Monitoring 
simultaneously the effects of optogenetic driving on the circuit using neural recording 
either by multielectrodes, voltage sensitive dyes or genetically encoded indicators may be 
advantageous in this context. 
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Modulation of structures remote from the epileptic origin 
The studies described above have all focused on modulating seizure activity found 
directly at the epileptic focus or site of injury. Targeting remote structures projecting to 
different areas involved in seizure genesis and propagation can have unique advantages 
since seizures may arise from multiple structures or discrete networks in the brain32. 
Indeed, electrical stimulation of structures remote from epileptic foci such as the 
cerebellum33–37, thalamus12,38–44, subthalamic nucleus45–47, and caudate48–50 have shown to 
be beneficial in reducing seizures in human patients. Optogenetic control of some of 
these remote structures have also been utilized to suppress seizure activity in various 
rodent models. 
 Paz et al. targeted thalamocortical neurons with an optogenetic strategy that 
interrupted electrographic and behavioral seizures in a cortical seizure model in rats51. In 
this study, rats were given a focal cortical stroke that resulted in hyperexcitability of 
thalamocortical neurons. Optogenetic inhibition of glutamatergic thalamocortical neurons 
via an AAV encoding CaMKIIα-eNphR3.0 was subsequently shown to interrupt 
electrographic and behavioral seizures when light illumination was manually switched on 
during seizure. By modulating the activity of thalamocortical neurons, the authors were 
able to demonstrate the potential benefits of targeting structures that lie upstream from 
areas of seizure activity. 
 Krook-Magnuson et al. investigated the role of the cerebellum in controlling 
spontaneous temporal lobe seizures by optogenetically targeting parvalbumin-expressing 
neurons  (e.g. Purkinje cells) in the medial (vermis) and lateral (lobulus simplex) 
cerebellar cortex of mice52. They found that interruption of cerebellar activity (either by 
 11 
excitation with ChR2 or inhibition with NpHR) in the lateral or medial cerebellum was 
able to reduce seizure duration. In contrast, only excitation of PV+ Purkinje cells in the 
medial cerebellum was able to reduce seizure frequency in addition to duration. 
 Soper et al. subsequently demonstrated that activation of the superior colliculus 
via ChR2 was able to attenuate seizure activity in various rat models of epilepsy53. These 
effects were seen on seizures involving the forebrain and brainstem (induced by systemic 
pentylenetetrazol administration), complex partial seizures (induced by focal bicuculline 
injection in the area tempestas), absence seizures (induced by systemic gamma 
butyrolactone administration), and brainstem seizures (in genetically epilepsy prone rats).  
The fact that modulation of a single area in the brain could reduce seizure activity found 
in different models of epilepsy illustrates the potential of targeting remote structures that 
have broad influence on various networks. The cell-type specificity of optogenetic 
approaches can further refine the effects that these remote structures have on the areas 
they project to. 
 
Seizure-responsive optogenetic intervention 
A major clinical goal for neuromodulatory devices is to be able to deliver therapy only 
when it is needed (i.e. only in response to a seizure). The Responsive Neurostimulation 
System (RNS) by NeuroPace14 is a good example of an implantable device used in 
humans where electrical stimulation is delivered in response to detection of a seizure 
event (closed-loop) as opposed to delivering electrical stimulation either continuously or 
at pre-determined intervals (open-loop). Devices that are able to deliver therapy in a 
closed-loop fashion not only reduce side-effects related to stimulation, but also improve 
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the efficiency and longevity of these devices by conserving battery power. Development 
of similar devices which can deliver light in response to seizure activity in real time will 
be a necessary goal for optogenetic therapies to find a clinical application in humans, 
given the power required for light delivery, the possibly deleterious effects of continuous 
light delivery (e.g. by heating), and possible effects on continued channel function (e.g. 
habituation).  
 Optogenetic stimulation using detection approaches analogous to those used in the 
clinically-approved RNS system have been demonstrated by Paz et al. and Krook-
Magnuson et al in rodents. Paz et al. 51 expanded upon their open-loop approach for 
interrupting thalamocortical seizures,by developing a method to automatically trigger 
optical stimulation when the EEG line-length crossed a certain threshold that was 
indicative of a seizure event. Using this closed-loop approach, the authors were able to 
detect and silence seizures within 1s of seizure onsets. Krook-Magnuson et al.54 took a 
more comprehensive approach of utilizing a closed-loop seizure detection algorithm to 
either silence excitatory principal cells or excite inhibitory interneurons in the mouse 
hippocampus. In this study, transgenic mice expressing NpHR in principal cells 
(CaMKIIα-NpHR) or ChR in GABAergic interneurons (Parvalbumin-ChR) were 
generated. These mice were then injected with kainic acid into the dorsal hippocampus to 
generate a chronic model of temporal lobe epilepsy. The authors were able to detect 
subsequent spontaneous seizures using custom software that utilized features such as 
signal power, spike waveform, and frequency. Upon detection of seizures in CaMKIIα-
NpHR mice, optogenetic inhibition of principal cells ipsilateral to the kainate injection 
stopped 58% of seizures within 5s of light illumination and reduced the mean seizure 
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duration by 70%. Upon detection of seizures in PV-ChR mice, optogenetic excitation of 
PV-positive interneurons ipsilateral to the kainate injection stopped 59% of seizures 
within 5s of light illumination and reduced the mean seizure duration by 43%. Across all 
animals, optogenetic intervention reduced behavioral seizures by 29.6%. This same 
approach was utilized to specifically inhibit granule cells of the dentate gyrus of the 
hippocampus (with transgenic mice), which was shown to stop 75% of seizures within 5s 
of light delivery and reduce the seizure duration by 66%55. 
 These studies have demonstrated the possibility of detecting and suppressing 
seizure activity with optogenetics in real time. Early detection and intervention of seizure 
activity has been particularly valuable for patients with epilepsy because epileptic foci 
could be targeted to limit seizure generalization and altered levels of consciousness. With 
the ability to modulate circuits with the cell type specificity of optogenetics, these closed-
loop approaches to seizure suppression can potentially achieve even greater efficacy with 




Figure 1.3.1. Optogenetic approaches to halting seizure activity. Optogenetics can 
be utilized to target specific cell types in the epileptic network directly at the seizure 
focus, remote modulators of the seizure focus, or downstream propagators of seizure 
activity. Light can either be delivered manually in an open-loop fashion, or 
automatically in response to a detected seizure (closed-loop). 
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Table 1.3.1. Summary of optogenetic approaches used for epilepsy. 
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Abbreviations: GC: granule cells; NpHR: Halorhodopsin; ChR2: Channelrhodopsin; 
BM: bicuculline methiodide; Pcp: Purkinje specific; PV: parvalbumin specific; GEPR: 
genetically epilepsy prone rats; GB: gamma butyrolactone; 4-AP: 4-aminopyridine. 
 
1.4 Current challenges impeding effective translation of optogenetics 
As summarized in the previous section, multiple optogenetic approaches have now been 
utilized to halt or suppress seizure activity in various animal models of epilepsy. 
Optogenetics has also been directly utilized as a therapy for treating other diseases such 
retinopathies, diabetes, pain, Parkinson’s57, and stroke58. This technique has therefore 
demonstrated great clinical value as a potential therapy for treating various diseases. The 
challenge now lies in translating these approaches to more clinically-relevant animal 
models.  
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However, several technical challenges need to be addressed before optogenetics 
can be effectively scaled to the brains of larger and more complex animal models. One 
major challenge is light delivery into the brain. Conventional approaches rely on 
surgically implanted fiber optics for delivering light into the brain, which are not ideal 
due to their hardware dependency, associated tissue damage, and limited volume of 
illumination. This hardware dependency comes from the need of external light sources 
such as lasers or LEDs to provide the driving light. Although advancements have been 
made in light delivery technology (e.g. miniaturized LEDs, wireless stimulators, optical 
commutators, etc.), these devices are still not fully hardware-independent. Another major 
problem with external light sources is their limited volume of illumination due to light 
scatter and attenuation as it travels though brain tissue. In fact, most of the light coming 
out of a fiber optic is completely attenuated within 1 mm from the fiber tip59. Although 
various approaches have been taken to increase light transmittance (e.g. multi-fiber 
probes, more sensitive/longer wavelength opsins60), it is unclear how scalable these will 
be to the much larger non-human primate or human brain. 
 Instead of relying on external light sources for driving optogenetic probes, we 
have explored the option of using biological light sources (i.e. bioluminescence from 
luciferase enzymes) since they can be genetically encoded, are hardware-independent, 
and readily scalable to illuminate multiple or large structures in the brain. The next 
chapter will describe basic concepts and describe methods I have developed for detecting 





BIOLUMINESCENCE: AN ALTERNATIVE LIGHT SOURCE FOR 
OPTOGENETIC APPLICATIONS 
 
 In this chapter, I describe practical methods and principles I have developed for 
generating and detecting bioluminescence from live cells and animals. We systematically 
tested various components of our live cell imaging microscope to optimize it for long 
term bioluminescence imaging. High resolution bioluminescence images from live 
neurons were obtained with our microscope setup and could be continuously captured for 
several hours with no signs of phototoxicity. Bioluminescence from the mouse brain was 
also imaged non-invasively through the intact skull with a conventional luminescence 
imager. These methods demonstrate how bioluminescence can be routinely detected and 
measured from live cells and animals in a cost-effective way with common reagents and 
equipment. 
2.1 Introduction 
Conventional optical techniques for live cell imaging have generally relied on the use of 
various fluorescent proteins or synthetic molecules. These imaging techniques require an 
exogenous light source to excite the fluorescent molecules, where they enter a higher 
energy state and subsequently emit light of a specific wavelength as they return to their 
ground state. Fluorescent molecules have proven to be exquisitely versatile reporters for 
live cell imaging because they span a broad spectrum of colors and can be detected with 
very high spatial and temporal resolution. Many important neuroscience questions 
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regarding cellular anatomical structures, neuronal circuitry, molecular interactions, brain 
dynamics, and brain pathology have been addressed with the use of fluorescent 
molecules. 
 In contrast to fluorescence, bioluminescence is light generated from an enzymatic 
reaction and is routinely demonstrated in nature by various bioluminescent marine 
species, arthropods, fungi, and bacteria. These organisms generate light via a 
chemiluminescent reaction, in which a chemical substrate (e.g. luciferin) is oxidized by 
an enzyme (e.g. luciferase). Bioluminescence is therefore produced without any 
excitation light source and persists as long as the substrate is present. A variety of 
bioluminescent proteins spanning a broad spectrum of colors and emission properties 
have been identified and their genes cloned; the major ones used in neuroscience research 
are summarized in Table 2.1. 
Table 2.1: common luciferases used in neuroscience research 
  
 Bioluminescence imaging differs from fluorescent readouts in several aspects 
that, depending on the specific application, can be advantageous or disadvantageous. One 
major advantage of fluorescent molecules is that they can be far brighter than 
bioluminescent proteins. One reason is that they can be made brighter by simply 
increasing the amount of excitation light, whereas bioluminescence intensity is strictly 






FLuc Firefly 560 Y D-luciferin 61–71 
VLuc 






480 N Coelenterazine 65,72–74 
GLuc Gaussia 
princeps 





470 N Coelenterazine 77–81 
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limited by the number of substrate molecules being catalyzed by the luciferase. Due to 
the relative dimness of bioluminescent proteins, longer exposure times are generally 
needed to collect a number of photons comparable to that of a fluorescent molecule. 
Bioluminescence imaging therefore generally has a limited temporal resolution compared 
to that of fluorescence imaging82. 
 On the other hand, several unique properties of luciferase reporters also make 
bioluminescence an attractive imaging modality. First, bioluminescent signals generally 
have a higher signal-to-noise ratio. This is due to the fact that background luminescence 
is negligible compared to the signal produced from the luciferase reaction83. 
Bioluminescent signals can therefore be much more sensitive than fluorescent signals, 
which generally have to compete with background auto-fluorescence. Second, 
bioluminescence does not require excitation light, eliminating the risk of photobleaching 
and phototoxicity that is associated with fluorescence imaging84. Bioluminescent signals 
are therefore well suited for live cell imaging and can be recorded for much longer 
timescales compared to fluorescent signals without damaging reporter molecules or cells. 
Lastly, since bioluminescence requires no exogenous excitation light sources, it is a 
suitable optical readout for imaging light-sensitive cells such as retinal neurons. 
Luciferase proteins have also undergone significant evolution in their versatility as 
genetically encoded reporters for neuroscience research. Similar to their fluorescent 
counterparts, luciferase proteins can also be targeted to specific regions in the cell with 
the use of trafficking or localization signal sequences to allow for imaging of subcellular 
structures over time72. The concept of fluorescence resonance energy transfer (FRET) has 
also been translated to bioluminescent proteins to measure molecular interactions. In this 
instantiation, both the intensity and spectral properties of bioluminescent proteins are 
altered when they are associated with fluorescent proteins in a process termed 
bioluminescence resonance energy transfer (BRET)85–87. Luciferase proteins have also 
been engineered to respond to small molecules such as calcium and ATP72, allowing 
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them to be used for measuring changes in cellular dynamics such as neuronal activity. 
Protein engineering techniques have also led to the development of brighter and longer 
wavelength luciferases that are well suited for in vivo imaging88–92. 
 In the rest of the chapter, I discuss advantages and disadvantages of the various 
methods we have utilized for detection and quantification of bioluminescent signals from 
live cells and animals. 
2.2 Measuring bioluminescence in vitro 
2.2.1 Results and discussion 
 Image brightness is directly related to the light-gathering power of the objective 
(numerical aperture, NA) and inversely related to the image magnification (M): 
brightness ∝ (NA/M)2. We have therefore maximized the image brightness of our 
samples by optimizing three components of our microscope: the objective, camera, and 
intermediate optics. 
 In selecting an appropriate objective lens for bioluminescence imaging, we aimed 
at finding one with the highest numerical aperture and lowest workable magnification. In 
comparing various objective lenses, we found that objectives with higher NA produced 
brighter, higher resolution images (Figure 2.2.1B vs. 2.2.1A). Lower magnification 
objectives were also able to produce higher resolution images (Figure 2.2.1D vs 2.2.1C). 
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 We utilized an intermediate demagnifying lens on a camera mount in order to 
allow more light to be focused onto a smaller area of the camera chip. Each pixel in the 
illuminated area of the chip therefore receives more light, producing a brighter image. 
We found that greater demagnification produced brighter images with sufficient spatial 
resolution to visualize detailed cellular morphology (Figure 2.2.2A vs. 2.2.2B). Note that 




SNR: 2.74 SNR: 40.68 
SNR: 10.99 SNR: 4.16 
0.7 NA 1.0 NA 
40X 20X 
 
Figure 2.2.1. Objective comparison. Bioluminescence images from cultured HEK 
cells expressing luciferase with the following objectives: (A) LUCPlanFL 60x 0.7NA, 
(B) LUMPlanFLN/W 60x 1.0NA, (C) UPlanFl 40x oil 1.3NA, and (D) UPlanSApo 
20x 0.75NA. Note that HEK cells in A and B were transfected with Gaussia 
luciferase while cells in C and D were transfected with Renilla luciferase. 
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field of view requirements must be carefully considered. 
 
 There are numerous camera options currently available for low-light optical 
imaging. Charge-coupled device (CCD) cameras are the most popular choice and rely on 
the photoelectric effect to convert a light signal into an electrical signal. The readout 
noise of CCD devices was significantly reduced with the advent of electron multiplying 
charge-coupled devices (EMCCD), making these cameras especially well-suited for low-
light imaging applications. Scientific CMOS (sCMOS) devices are a relatively new type 
of sensor that also offers extremely low readout noise and wide dynamic range, making 
them a cost-effective alternative for imaging in low-light conditions. We have therefore 
compared several CCD, EMCCD and sCMOS cameras for bioluminescence imaging 
(Figure 2.2.3). All of the cameras tested were able to produce bioluminescence images 
with relatively low background and short exposure times (1-10s). Even though EMCCD 
cameras generally outperform sCMOS devices at very low light levels, our images were 
qualitatively similar (most likely due to the fact that RLuc and GLuc are relatively bright 
luciferases). One should therefore select a camera based on the level of sensitivity 
A. B. 
SNR: 4.07 SNR: 3.70 
 
Figure 2.2.2. Intermediate lens comparison. Bioluminescence images of dissociated 
cortical neuron cultures expressing Renilla luciferase using a 0.3x intermediate lens 
(A) and a 0.5x intermediate lens (B). Both images were taken with an UAPO 40x 
1.35NA oil objective and a sCMOS camera. 
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required, as the price difference between EMCCD and sCMOS cameras can be quite 
significant. 
 Due to the relatively long exposure times required for bioluminescence imaging, 
we found that it was important to reduce the amount of ambient light in the room as much 
as possible to reduce background noise. We routinely turned off or covered light sources 
(such as an arc lamp for fluorescence observation) near the microscope before 
bioluminescence imaging. We found that blackout curtains were especially effective at 
isolating the microscope and camera from any potential light contamination. Cooling the 
camera to the lowest temperature setting also helped reduce background by limiting dark 
current noise. 
 The danger of phototoxicity and photobleaching limits the effectiveness of long-
term live-cell imaging with fluorescent molecules. In contrast, we have demonstrated that 
bioluminescent reporters can be used to image live cells for extended periods of time 
without any apparent adverse effects. The substrate was supplied by a perfusion system, 
resulting in a long-lasting bioluminescent signal which could be detected over several 
hours. We did not observe any apparent adverse effects during this period, making this 
approach suitable for imaging cellular processes that are directed over long timescales, 
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Figure 2.2.3. Camera 
comparison. Bioluminescence 
images of HEK293 cells 
transfected with Gaussia 
luciferase (LMO2) taken with 
various cameras: (A): Coolsnap-
ES (Photometrics); (B): 
Coolsnap-FX (Photometrics); 
(C): ImagEM X2 EMCCD 
(Hamamatsu); (D): iXon Ultra 
897 EMCCD (Andor). Average 
bioluminescence signal per cell 
area was quantified for each 
image over the capture series (E). 
Signal-to-noise ratio (SNR) 




Preparation of coelenterazine substrate 
The substrate for Renilla and Gaussia based luciferases, coelenterazine (CTZ), is 
typically dissolved in nonpolar solvents such as ethanol or methanol. These solvents are 
not ideal for live cell imaging due to their inherent toxicity. We therefore recommend 
solubilizing CTZ in aqueous solution with the help of inert chemical agents such as ß-
cyclodextrin as described by Shimomura et al.93 or by utilizing commercially available 
solvents. After solubilization, CTZ can be aliquoted and stored at -20ºC. It is important to 
note that CTZ should be protected from light to prevent auto-oxidation. 
 
Cell culture and transfection 
HEK293 cells were passaged regularly in Dulbecco’s Modified Eagle Medium (DMEM, 
with 10% FBS, 1% penicillin/streptomycin) and seeded to 90% confluency on glass 
cover slips the day before transfection. HEK cells were transfected with expression 
vectors encoding membrane-localized Renilla luciferase73  and membrane-localized 
Gaussia luciferase protein94 using Lipofectamine 2000 (Invitrogen). Transgene 
expression was confirmed by fluorescence microscopy the following day. 
Dissociated cortical neuron cultures were derived from E18 rat embryos. Cortical tissue 
was digested with 2mg/mL papain and dissociated by mechanical trituration before 
seeding onto 18 mm diameter German glass coverslips coated with 50 µg/mL poly-D-
lysine (Sigma). Neuronal cultures were grown in serum-free Neurobasal media (w/ 1x 
B27 supplement, 0.5 mM Glutamine) and media was changed (half-volume) every 3-4 
days. Cortical neuron cultures were transduced with viral vectors encoding luciferase 2-3 




Live cell bioluminescence imaging 
Bioluminescence images were taken on an Olympus inverted fluorescence microscope 
equipped with a variety of objectives, c-mount adaptors, and cameras: 
Objectives Adaptors Cameras 
PlanApo 60x oil 1.4NA 0.5x Coolsnap-ES CCD (Photometrics) 
UPlanFl 40x oil 1.3NA 0.3x Coolsnap-FX CCD (Photometrics) 
LUMPlanFLN W 60x 
1.0NA 
 ImagEM X2 EMCCD 
(Hamamatsu) 
UPlanSApo 20x 0.75NA  iXon Ultra 897 EMCCD (Andor) 
LucPlanFL 60x 0.7NA  QuantEM EMCCD (Photometrics) 
  OptiMOS sCMOS (Photometrics) 
 
Cells cultured on glass coverslips were transferred to a perfusion chamber (Warner 
Instruments) containing phenol-free media at the time of imaging to minimize light 
absorption and maximize transmission of bioluminescence through the media (this is 
especially important for upright microscopes). The cells were then checked under 
fluorescence to confirm transgene expression and determine the right depth of focus for 
bioluminescence imaging. The microscope was then switched to an empty filter position 
to collect whole-spectrum bioluminescence. 
 Images were collected using the open-source Micromanager image acquisition 
software. Camera settings were standardized and optimized by cooling the chip to the 
lowest temperature (to minimize dark current) and maximizing the gain. Binning was 
used only when it was necessary to produce visible images. All of the background light 
sources in the room (windows, doors, electronics) were covered with blackout material 
and images were collected at various exposure times (1-40s). Long term bioluminescence 
images were acquired by using the multi-acquisition feature of Micromanager and a 
perfusion system to deliver CTZ during the imaging period (up to 3 hours). 
Image quality was estimated by calculating the signal-to-noise ratio (SNR) of captured 
images. SNR was calculated by dividing the mean pixel intensity of the bioluminescence 
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image to the standard deviation of the pixel intensity from a background image (or region 
with no cells) in ImageJ. 
2.3 Measuring bioluminescence in vivo 
2.3.1 Results and Discussion 
 In vivo fluorescence imaging is often compromised by high non-specific 
background from tissue and cells (auto-fluorescence). In contrast, background 
bioluminescence from tissues not expressing luciferase is negligible. This property of 
bioluminescence makes it an ideal signal for imaging whole animals where the number of 
luciferase-expressing target cells is generally few compared to the surrounding non-
expressing tissue. We assessed the usability of Renilla luciferase for in vivo imaging and 
found that the bioluminescence signal was strong enough to allow detection of signals 
through the intact skull (Figure 2.3.1a, b). Special consideration of the route of substrate 
administration is needed when selecting a luciferase to use for in vivo bioluminescence 
imaging. Firefly luciferase (Fluc) has been frequently used for bioluminescence imaging 
in animals due to the relatively ease of the intraperitoneal route of substrate (D-luciferin) 
administration. Although we have demonstrated that coelenterazine can also be delivered 
intraperitoneally, Renilla luciferase is maximally effective when the substrate is 
administered via intravenous routes (Figure 2.3.1c). Since beetle (e.g. Firefly) and 
marine (Renilla, Gaussia) luciferases utilize different luciferin substrates, it is therefore 
feasible to multiplex them together due to absence of crosstalk between the two systems.  
 The low background with bioluminescence makes in vivo bioluminescence 
imaging particularly sensitive for detecting signals from small areas over extended 
periods of time. In fact, bioluminescence imaging has been successfully used for 
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applications from tracking transplanted cells95,96 to monitoring cellular processes such as 
neurodegeneration, inflammation, and neurogenesis97. Although in vivo bioluminescence 
signals provide limited spatial information directly, the cell-type specificity of luciferase 
expression provides indirect spatial information because any detected bioluminescence 
should ostensibly be coming only from cells expressing luciferase. 
 
 
Figure 2.3.1. In vivo bioluminescence imaging. Bioluminescence imaging of an 
adult mouse injected with AAV encoding Renilla luciferase in the cortex. 500 µg 
CTZ was delivered intravenously (A) or intraperitoneally (B). Color bar depicts 






 For imaging the mouse brain, an adeno-associated virus (AAV) encoding Renilla 
luciferase (RLuc) was injected into the cortex of white mice (-1.58 AP, -0.75 ML, -0.8 SI 
and -1.58 AP, -1.75 ML, -0.5 SI). After 2 weeks, the fur was shaved off the head and the 
animals were anesthetized with ketamine/xylazine before bioluminescence imaging. 500 
µg of CTZ was administered either intraperitoneally or intravenously (via tail vein 
injection). Bioluminescence images were captured with the animals under anesthesia 
using a conventional luminescence imager (Fuji LAS-3000). Sequential images of 20s 
exposure time were captured and the total signal intensity was quantified in ImageJ to 
achieve a bioluminescence signal time course. Pseudocolor images are displayed showing 
the relative bioluminescence signal. All procedures were performed in accordance with 
the US National Institutes of Health guidelines for animal research and were approved by 
the Institutional Animal Care and Use Committee at Emory University. 
2.4 Conclusion 
We have demonstrated how bioluminescent proteins can be effectively used as an optical 
reporter for both in vitro and in vivo settings. Given the proper detection equipment and 
scientific question, bioluminescence offers several unique advantages over conventional 
fluorescence readouts. The major advantage of using bioluminescent signals is that they 
are detected over little to no background noise, enabling long term imaging applications 
with no risk of phototoxicity or artifact. With the development of brighter and more 
responsive luciferase proteins, the use of bioluminescent reporters in neuroscience 










With the ability to generate and characterize bioluminescence from luciferase enzymes 
(Chapter 2), this chapter will now describe my efforts in coupling these biological light 
sources to light-sensitive opsins to drive optogenetic inhibition. We have bypassed the 
challenges of external light delivery by directly coupling a bioluminescent light source (a 
genetically encoded luciferase) to an inhibitory opsin, which we term an inhibitory 
luminopsin (iLMO). iLMO was shown to suppress action potential firing and 
synchronous bursting activity in vitro in response to both external light and luciferase 
substrate. iLMO was further shown to suppress single-unit firing rate and local field 
potentials in the hippocampus of anesthetized rats. Finally, expression of iLMO was 
scaled up to multiple structures in the basal ganglia to modulate rotational behavior of 
freely moving animals in a hardware-independent fashion. This novel class of 
optogenetic probes demonstrates how non-invasive inhibition of neural activity can be 
achieved, which adds to the versatility, scalability, and practicality of optogenetic 
applications in freely behaving animals. 
 
3.1 Introduction 
Optogenetic techniques have revolutionized the field of neuroscience because they have 
given scientists the ability to selectively activate or inhibit neural activity in the context 
of exquisitely complex neural circuitry98. These techniques rely on the use of light-
sensitive ion channels or pumps (opsins), which are expressed in a cell-type specific 
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manner in the brain and activated by an external light source such as a laser or light-
emitting diode (LED).  
 Although optogenetic techniques generally work well in small rodents, several 
technical challenges with light delivery into the brain still need to be addressed before 
these techniques can be routinely used in freely behaving animals or translated into larger 
and more complex animal models. The most common solution for delivering light into 
the brain is via a surgically implanted optical fiber coupled to an external light source. 
Not only do these chronically implanted optical fibers pose risk for infection and tissue 
damage, but they also raise practical impediments (e.g. limited range of movement or 
need for extra hardware such as optical commutators) for conducting experiments with 
freely moving animals. Transmission of external light through the brain is also extremely 
inefficient due to light scatter and tissue absorption99,100. In fact, most of the light emitted 
from an implanted fiber optic is completely attenuated within 1 mm of the fiber tip101. 
Optogenetic applications in other tissues (e.g. heart102 and peripheral nerves103) share 
similar challenges with light delivery, where light scatter and attenuation can also be a 
significant problem104. While progress has been made towards developing optogenetic 
tools that require less light (i.e. more sensitive and red-shifted opsins60,105,106), the 
scalability of this approach to larger non-human primates or human patients is still 
unclear. 
 We have bypassed the challenges of external light delivery by directly coupling 
bioluminescent proteins to conventional light-sensitive opsins. Specifically, we have 
utilized luciferase enzymes (which emit bioluminescence in the presence of a chemical 
substrate, luciferin) as an alternative light source for activating light-sensitive opsins. 
Since luciferase enzymes can be genetically encoded and expressed together with opsins 
in a cell-type specific manner, these bioluminescent light sources obviate any need for 
chronic implants or external hardware for delivery of light into the brain. A genetically 
encoded light source also offers much versatility in illuminating large, multiple, or 
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complex structures in the brain due to the ability to scale up expression in a cell-type 
dependent manner. 
 Building upon the previously demonstrated feasibility of coupling bioluminescent 
proteins to excitatory channelrhodopsins in a single fusion protein termed a luminosopin 
(LMO)94, we describe here a new class of inhibitory luminopsins (iLMOs) consisting of 
Renilla luciferase (Rluc) and Natronomonas halorhodopsin (NpHR) and demonstrate 
their ability to silence neural activity in vitro and in vivo in response to both external light 
and chemical substrate. This new class of optogenetic probes not only allows for 
optogenetic inhibition without external hardware, but also permits multi-modal (i.e. 
optical and chemical) methods of neuromodulation that can result in varying temporal 
effects. 
 Here we demonstrate how the versatility of conventional light-sensitive opsins 
can be increased when they are converted into luminopsins, enabling a readily scalable 
and non-invasive means of neuromodulation that may have unique advantages over other 
chemical-genetic approaches. 
 
3.2 Design and construction of iLMOs 
3.2.1 Results 
 
In search of a luciferase most suitable for activating NpHR, we characterized 
bioluminescence from several luciferase proteins that have compatible emission spectra 
with NpHR: a red-shifted Renilla luciferase (TagRFP-RLuc107), a brighter Renilla 
luciferase variant (Nano-lantern72), and firefly luciferase (FLuc108). HEK293 cells were 
transiently transfected with these luciferases and were characterized in a plate reader by 
measuring bioluminescence intensity and emission spectrum. The emission spectra for all 
the luciferases peaked at ~525-nm, with TagRFP-RLuc and Nano-lantern having a wider 
emission spectrum compared to Fluc (Figure 3.3.1a) due to bioluminescence resonance 
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energy transfer (BRET) 109,110. Although the red-shifted emission spectrum of TagRFP-
RLuc appeared to be more preferable for activating NpHR, total luminescence from 
TagRFP-RLuc was significantly lower than that from Nano-lantern by a factor of 12.3 (p 
< 0.001 by one-way ANOVA with Bonferroni posthoc test; n = 3 for each group) (Figure 
3.2). Fluc did not appear to be a suitable luciferase because it is ATP dependent (which 
could potentially influence neural activity directly111) and its bioluminescence intensity 
was lower than the RLuc variants by several orders of magnitude. We therefore decided 
to couple TagRFP-Rluc and Nano-lantern to NpHR by cloning each luciferase to the 3’ 
end of NpHR to create two fusion proteins, which we term iLMO1 and iLMO2 (Figure 
3.2.1), respectively. Endoplasmic reticulum export sequences described by Gradinaru et 
al.24 were also included at the 3’ end of the fusion protein to improve membrane 
trafficking. Here we present the results for iLMO2 since it proved to be more robust. The 






Figure 3.2.1. Schematic representation of the iLMO2 
fusion protein. iLMO2 consists of Nano-lantern, a Renilla 





Plasmid construction. All constructs were initially cloned into the PCDNA3 backbone 
(Invitrogen) for ease of comparison. The luciferase constructs (TagRFP-Rluc8.685 was a 
gift from Dr. Sanjiv Gambhir; Firefly luciferase108 was a gift from Dr. Phil Sharp, 
Addgene plasmid #11510; Nano-lantern72 was a gift from Dr. Takeharu Nagai, Addgene 
plasmid # 51970) were all PCR amplified and cloned into the PCDNA3 vector for direct 
comparison of expression and bioluminescence. The NpHR coding sequence was PCR 
amplified from the pAAV-eNpHR3.0-EYFP plasmid (gift from Dr. Karl Deisseroth) and 
inserted into the PCDNA3 vector. The EYFP coding sequence was digested out of this 
plasmid using EcoRI/NotI restriction sites to leave a backbone containing NpHR. iLMO1 
was created by PCR amplifying out the TagRFP-Rluc8.6 cassette and inserting it in-
frame downstream of NpHR. iLMO2 was created in a similar fashion, where the Nano-
lantern cassette was PCR amplified (Forward primer: 5' 
ATCGGAATTCGTGAGCAAGGGCGA, Reverse primer: 5' 
ATCGCTCGAGTTACACCTCGTTCTCGTAGCAGAACTGCTCGTTCTTCAGCAC) 
and cloned downstream of the NpHR coding sequence. Both constructs also included an 
ER-export sequence112 at the 3’ end of the fusion protein. The iLMO1 and iLMO2 
cassettes were subsequently cloned into the FUGW lentiviral backbone and the pAAV 
backbone for production of 2nd generation lentivirus and AAV2/9, respectively. 
3.3 Characterization of iLMOs in HEK293 cells 
3.3.1 Results 
 
We first examined the bioluminescence from iLMO2 and compared it to that of Nano-
lantern in transfected HEK293 cells to see whether the creation of the fusion protein had 
altered the functionality of the luciferase. Both the bioluminescence intensity and 
emission spectrum of iLMO2 were not significantly different from that of Nano-lantern 
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alone (Figure 3.3.1a, b), which suggests that the functionality of the luciferase moiety is 
preserved in the fusion protein.  
 Next, we evaluated the functionality of the NpHR moiety in iLMO2. Judging 
from the localization of the fluorescence tag, HEK293 cells transfected with iLMO2 
efficiently expressed the fusion protein in the cell membrane (Figure 3.3.1c). Whole-cell 
patch clamp recordings revealed that iLMO2-expressing HEK293 cells produced 
hyperpolarizing outward currents in response to green lamp illumination (Figure 1e), 
which was not significantly different in peak amplitude from cells expressing NpHR 
alone or from cells co-expressing NpHR and Nano-lantern separately (p > 0.05; one-way 
ANOVA with Bonferroni posthoc test; n = 5 for all groups). These results therefore 
indicated that NpHR functionality was not significantly affected by fusion or co-
expression with Nano-lantern. 
 We next tested the capability of luciferase-driven activation of NpHR in iLMO2-
expressing HEK293 cells. CTZ application in cells expressing iLMO2 generated outward 
currents that were significantly greater than the negligible CTZ-induced current in cells 
expressing NpHR alone (p < 0.05; one-way ANOVA with Bonferroni posthoc test; n = 5 
for all groups), indicating a specific effect of CTZ on cells expressing iLMO2 and 
bioluminescence-mediated photocurrent (Figure 3.3.1d). Interestingly, the response of 
iLMO2-expressing cells to CTZ was not significantly different from cells co-expressing 
Nano-lantern and NpHR separately, which suggests that bioluminescence from Nano-
lantern can activate NpHR whether or not they are physically coupled together. 
 To assess the efficiency of bioluminescence-driven activation of NpHR, the 
coupling efficiency (peak CTZ-induced photocurrent divided by peak lamp-induced 
photocurrent) was calculated. The mean coupling efficiency was higher when Nano-
lantern and NpHR were expressed together as the iLMO2 fusion protein compared to 
when they were co-expressed separately (Figure 3.3.1e), but this difference was not 
statistically significant (p > 0.05; one-tailed Student’s t-test, n = 5 for each group). 
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 These results demonstrate that Renilla luciferase can activate NpHR when they 
are either co-expressed or coupled together as a single fusion protein. Although co-
expression of opsin and luciferase has been shown to be technically feasible by us and 
others113, the single fusion protein approach provided more robust responses and practical 





Figure 3.3.1. Characterization of iLMO2 in HEK293 cells demonstrates potential 
of both direct light and luciferase-driven activation of NpHR. (a) Emission spectra 
and (b) Total luminescence measured from transfected HEK293 cells expressing 
various luciferases (Nano-lantern, TagRFP-Rluc, Firefly) and iLMO2. (c) 
Fluorescence image showing membrane-localized expression of iLMO2 in transfected 
HEK293 cells. Scale bar: 50 µm (d) Average peak photocurrent responses to green 
lamp illumination and CTZ measured from HEK293 cells transfected with NpHR and 
Nano-lantern separately (NpHR + Nano-lantern), iLMO2 fusion protein, and NpHR 
alone (n = 5 for each group). Mean responses to CTZ are significantly different (*p < 
0.05) but light responses were not significantly different (p > 0.05) by one-way 
ANOVA with Bonferroni posthoc test. (e) Coupling efficiency (peak photocurrent 
from CTZ divided by peak photocurrent from lamp) of transfected HEK293 cells 
expressing NpHR and Nano-lantern separately (NpHR + Nano-lantern) (n = 5), and 





Coelenterazine preparation. Coelenterazine-h was purchased from Promega and was 
solubilized in 20 mM β-cyclodextrin (Sigma) in PBS as described by Dr. Osamu 
Shimomura93. Frozen stock aliquots were kept at -20°C and protected from light. For 
rotational experiments, CTZ was purchased from Nanolight and solubilized in their 
proprietary Inject-a-lume solvent immediately before use. 
 
Cell culture and transfection. HEK293 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum (FBS) and 100U/mL 
Penicillin/Streptomycin at 37°C with 5% CO2, and were regularly passaged with 0.25% 
Trypsin/EDTA every 3-4 days. HEK293 cells were transfected with plasmids using 
Lipofectamine 2000 (Invitrogen) following manufacturer recommended protocols. 
Cortical neuron cultures were derived from E18 rat embryos. Cortical tissue was digested 
with Papain (2 mg/mL) and mechanically dissociated by trituration with a fire-polished 
glass pipette. Dissociated cortical neuron cultures were seeded on poly-D-lysine coated 
18 mm glass coverslips (NeuVitro) and were grown in Neurobasal media containing 1% 
FBS and 1X Glutamax (Invitrogen). The media was fully changed the day following 
plating with Neurobasal media containing B27 supplement and 1X Glutamax. Neuronal 
cultures were typically transduced with viral vectors 1 day in vitro at a multiplicity of 
infection (MOI) greater than 10 to ensure near 100% transduction efficiency. Half-
volume media changes were subsequently given every 3-4 days. 
 
Plate reader assay. For direct comparison of bioluminescence intensity, HEK293 cells 
seeded at the same density were transfected with 200 ng of luciferase construct (all in the 
PCDNA backbone) in triplicate wells  of a 96-well white luminescence plate (Costar). 
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Total luminescence was detected with a commercial plate reader (BMG Labtech) after 
adding CTZ or D-luciferin (Sigma) to each well (final concentration of 20 µM). The 
same gain and integration times were used for measuring all wells. For estimation of 
emission spectra, luminescence was similarly measured with the use of a filter wheel 
equipped with 420-nm, 485 nm, 520-nm, 544-nm, 584-nm, 590-nm, and 620-nm 
bandpass filters. 
3.4 Characterization of iLMO2 in cortical neurons 
3.4.1 Results 
 
 To express iLMO2 in neurons, the iLMO2 cassette was cloned into a lentiviral 
vector and used to transduce dissociated cortical neurons in vitro. Fluorescence 
micrographs showed strong membrane-localized expression of iLMO2 (Figure 3.4.1, 
left) with no obvious morphological signs of toxicity. After addition of CTZ, robust 
bioluminescence signal was detected and could be imaged with resolution comparable to 
that of fluorescence imaging (Figure 3.4.1, right). Whole-cell patch clamp recordings 
showed that neurons expressing iLMO2 generated hyperpolarizing outward currents in 
response to both direct lamp illumination and CTZ application (Figure 3.4.2a). Although 
direct light illumination was able to generate larger photocurrents than CTZ application, 
the difference was not statistically significant (p > 0.05; two-tailed paired Student’s t-test, 
n = 8 for each group). The time course of the CTZ-induced photocurrents corresponded 
to the bioluminescence signal that was simultaneously detected from the same cells, 
which suggests that the outward currents seen after CTZ application were due to the 
activity of luciferase. These effects were not directly caused by CTZ itself because 
negligible photocurrent responses were seen when CTZ was added to non-transduced 
cells. The coupling efficiency of iLMO2 in cortical neurons was 72.6 ± 14.4% (mean ± 
 41 
SEM; n = 8), which was significantly higher than that found in HEK cells (p < 0.05; one-
tailed Student’s t-test; n = 5).  
 
 Next, iLMO2 was tested in the context of suppressing both spontaneous and 
evoked action potentials in dissociated cortical neuron cultures. Similar to direct lamp 
illumination (Figure 3.4.2b, right), CTZ application was able to completely inhibit 
action potentials evoked by threshold-level (rheobase levels where action potentials are 
evoked ~50% of the time) current injections given at 1 Hz (Figure 3.4.2b, left). In 
addition, iLMO2 was able to completely suppress spontaneous action potential firing 
after CTZ application (Figure 3.4.2d). In contrast, action potentials evoked by supra-
threshold (action potentials evoked 100% of the time) current injections were only 
partially suppressed by CTZ (Figure 3.4.2d), which was most likely due to the inability 
of iLMO2 to overcome the relatively larger inward current injections. These experiments 
corroborate our previous findings in HEK293 cells and demonstrate that iLMO2 can 
inhibit neuronal firing in single cells in response to both external light and luciferase 
substrate. 
 Fluorescence Luminescence 
 
Figure 3.4.1. Bioluminescence and fluorescence images of cortical neurons 
expressing iLMO2. Left: fluorescence micrograph depicting dissociated cortical 
neurons expressing iLMO2. Right: bioluminescence image taken in the same field of 





Figure 3.4.2. Whole cell recordings of cortical neurons expressing iLMO2. (a) Representative 
voltage clamp recordings of a neuron expressing iLMO2 demonstrate hyperpolarizing outward 
photocurrents in response to CTZ (left, dashed line indicates time of CTZ addition) and green lamp 
illumination (right, green bar denotes period of illumination). Note that the outward current coincides 
with an increase in luminescence (top left). (b) Average peak photocurrent response to CTZ and green 
lamp illumination in neurons expressing iLMO2 fusion protein (n = 8). (c) Representative current 
clamp recordings from neurons expressing iLMO2 demonstrate complete suppression of action 
potentials (evoked by 1Hz threshold-level current injections) in response to CTZ (left, dashed line 
indicates time of CTZ addition) and green lamp illumination (right, green bar denotes period of 
illumination). A sustained hyperpolarizing response coincides with an increase in luminescence after 
CTZ addition. (d) Average percent inhibition of spontaneous (n = 3) and evoked (n = 6 for threshold-
level current injections; n = 4 for supra-threshold) action potentials in cortical neurons expressing 
iLMO2. Error bars indicate standard error of the mean. 
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 To test the ability of iLMO2 to silence neuronal activity of a population of 
neurons, we cultured cortical neurons on multielectrode arrays (MEAs) and transduced 
them with iLMO2 lentivirus. When cortical neurons are cultured on MEAs at high 
density, they spontaneously exhibit synchronous burst-firing activity across the 
culture114,115. Addition of CTZ inhibited burst-firing activity in a period of minutes, 
resulting in near-zero total firing rate across all the electrodes in the array (Figure 
3.4.3a). This effect persisted for up to 20 minutes before bursts returned and total firing 
rate gradually recovered back to baseline levels. Recovery back to baseline required 
several hours, which is consistent with the amount of time these cultures take to recover 
from transient suppression of bursting activity116. The synchrony (a measure of 
concurrent spike times across electrodes) of cultures expressing iLMO2 also transiently 
decreased during periods of suppressed burst-firing, confirming that CTZ was 
suppressing synchronous bursting activity. These changes induced by CTZ were not seen 
in sister control cultures that were not transduced with iLMO2 lentivirus (Figure 3.4.3b), 
indicating that CTZ was specifically acting through iLMO2. On average, multiunit 
activity in each electrode of the array slightly increased in control cultures after addition 
of CTZ (Figure 3.4.3c, black trace), whereas cultures expressing iLMO2 showed an 
unequivocal marked reduction in multiunit activity in each electrode of the array after 
addition of CTZ (Figure 3.4.3c, red trace). These results all suggest that iLMO2 is able 






Figure 3.4.3: iLMO2 is able to suppress 
synchronous bursting activity in vitro. (a) A 
representative multielectrode array recording 
of a culture transduced with iLMO2 fusion 
protein shows complete inhibition of 
spontaneous bursting activity after addition 
of CTZ (dashed line). Spontaneous bursting 
activity eventually returns to baseline levels 
over a period of several hours. In both (a) 
and (b) the middle trace shows array-wide 
firing rate, top trace shows corresponding 
raster (each color corresponds to a different 
 channel), and bottom trace depicts synchrony across two electrodes. (b) Representative 
multielectrode array recording of a sister control culture (un-transduced) showing no effect of CTZ 
on spontaneous bursting activity. (c) Average change in multi-unit firing rate (9 channels per 
culture) of 10 min intervals before, immediately after, and 6 hours after addition of CTZ in iLMO2 
expressing (dotted red lines, n = 6) and sister control cultures (dotted black lines, n = 3). Solid bold 




Viral vector production. iLMO2 lentivirus driven by the ubiquitin promoter (lenti Ub-
iLMO2) was made in-house based on methods described by Dr. Trono Didier117. In brief, 
293FT cells were grown in multiple 10 cm cell culture dishes to 90% confluency on the 
day of transfection. Each dish was then transfected with 7.5 µg Δ8.9 packaging vector, 3 
µg VSVG envelope vector, and 10 µg of the iLMO2 transfer vector by calcium 
phosphate precipitation. Transfection efficiency was confirmed the following day by 
fluorescence microscopy and lentivirus was subsequently harvested for 2 days following 
transfection. The harvested lentivirus was purified through a 0.45 µM PES filter and 
concentrated by ultracentrifugation to an approximate titer of 108 infectious particles/mL. 
AAV2/9 CAMKIIα-iLMO2 was produced by the Emory viral vector core at a titer of 
1012 viral genomes/mL. 
 
Intracellular recordings. Intracellular recordings were taken from 12 day old dissociated 
cortical neurons cultured on glass coverslips. The glass coverslips were transferred to an 
18 mm low profile recording chamber (Warner Instruments) and perfused using a Quick 
Exchange platform (Warner Instruments) with external solution containing 135 mM 
NaCl, 5mM KCl, 1 mM MgCl2, 2 mM CaCl2*2H2O, 10 mM HEPES, 10 mM Glucose. 
Whole cell patch clamp recordings were obtained with glass pulled recording pipettes 
with 5-10 mΩ resistance containing internal solution consisting of 120 mM potassium 
gluconate, 2 mM MgCl2, 1 mM CaCl2*2H2O, 10 mM EGTA, 10 mM HEPES, 2 mM 
ATP. Recordings were sampled at 10 kHz with an EPC-9 amplifier (HEKA) and 
Patchmaster software for online analysis and later exported to Matlab for offline analysis. 
Membrane potential was clamped to -60 mV for voltage clamp recordings while current 
was clamped at 0 ± 20 pA for current clamp recordings in order to maintain a resting 
membrane potential of -60 mV. Action potentials were evoked by either giving threshold-
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level (rheobase levels evoking spikes ~50% of the time) or supra-threshold level (spikes 
evoked 100% of the time) current injections. Bioluminescence imaging was concurrently 
taken throughout the whole cell recordings with a 1.35 NA oil immersion objective, 
0.35x demagnifying lens, and a scientific CMOS camera (QImaging). CTZ was bath 
applied through a 4 channel micro-manifold (AutoMate Scientific) to reach a final 
concentration of 40 µM in the recording chamber. Cells were illuminated through the 
objective with green light (532-554 nm TRITC filter cube at 35 mW/mm2) using an 
electronic shutter. Percent inhibition of spikes were calculated as the peak reduction of 
firing rate across the recordings taken in 10 s bins. 
 
In vitro multielectrode recordings. High density cortical neuron cultures grown on 
multielectrode arrays were prepared and recorded using the same equipment and methods 
described by Hales et al 118. Briefly, approximately 50,000 dissociated cortical neurons 
were seeded in each well of a 6-well multielectrode array (Multichannel Systems). Each 
well contained 9 recording electrodes, in which multiunit activity was detected and 
acquired by a custom-built NeuroRighter data acquisition system119. The cultures were 
covered with a Teflon lid to prevent evaporation and kept in a humidified incubator set at 
35°C and 5% CO2. The cultures were infected 1 day in vitro with Ub-iLMO2 lentivirus 
at >10 MOI to ensure near 100% transduction efficiency, and the media was subsequently 
changed (half-volume) every 3-4 days with Neurobasal media containing 2% FBS. 
Approximately 2 weeks later, the MEA was connected to a pre-amplifier located inside 
an incubator kept at 65% humidity, 35°C, and 5% CO2. Spiking activity in the cultures 
was confirmed and the MEA was allowed to equilibrate in the incubator overnight. On 
the day of the experiment, 5 µl of CTZ was added to the media of each culture to reach a 
final concentration of 12 µM. Recordings were taken up to 6 hours after addition of CTZ 
and analyzed offline using custom Matlab scripts. Synchrony was calculated using 
custom Matlab scripts developed by Quiroga et al120. Percent change in firing rate was 
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calculated by averaging the firing rate of each electrode in the culture across a 10 min 
window immediately after and 6 hours after the addition of CTZ. 
3.5 Characterization of iLMO2 in vivo 
3.5.1 Results 
 
Next, we examined the ability of iLMO2 to suppress neural activity in anesthetized and 
awake rats. The iLMO2 cassette was cloned into an adeno-associated viral (AAV) vector 
under the control of the CaMKIIα promoter, and the virus was stereotaxically injected 
into the dorsal hippocampus of rats to selectively target expression of iLMO2 to 
pyramidal cells of CA3 and CA1 (Figure 3.5.1a, right). A cannula-electrode consisting 
of a 16-channel microwire array and a guide cannula (Figure 3.5.1a, left) was fabricated 
and subsequently implanted in the same area, where each row of the array targeted a 
different pyramidal cell layer of CA3 and CA1. The cannula-electrode was then 
chronically implanted, which allowed for easy insertion of an injection cannula or optical 
fiber for intracerebral injections and optical stimulation, respectively, to the same area in 
each animal over multiple trials under anesthesia. Before each injection trial, single-units 
whose firing rate was significantly reduced by conventional photostimulation (525-nm or 
620-nm LED) were first identified for subsequent single-unit analysis. The optical fiber 
was then replaced with an injection cannula that contained either 2 µl of CTZ or vehicle. 
When CTZ was injected intracerebrally over 5 minutes, single-unit firing rate (of those 
units that responded previously to photostimulation) decreased and reached peak 
inhibition about 15 minutes after injection (Figure 3.5.2a, top and middle). The firing 
rate subsequently returned back towards baseline levels over the next 15 minutes. In 
addition to reducing single-unit firing rate, CTZ also reduced the low frequency power (1 
– 10 Hz) in the local field potential of the same electrodes (Figure 3.5.2a, bottom), 
indicating that the dominant theta rhythms in the hippocampus121 were suppressed. In 
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contrast, when vehicle was injected in the same animal as a control, an increase in single-
unit firing rate and no change in the local field potential were observed (Figure 3.5.2b). 
These trials of intracerebral CTZ and vehicle injection were repeated daily with an 
alternating order over a period of 5-7 days. The average peak response to CTZ (Figure 
3.5.3a, red trace) was comparable to conventional photostimulation by LEDs: single-
unit firing rate was reduced on average by 52.1 ± 5.4%, 37.5 ± 6.9%, and 45.0 ± 4.6% 
(mean ± SEM; n = 24 units each) by 620-nm light, 525-nm light, and CTZ, respectively. 
On average, vehicle injections increased single-unit firing rate by 44.6 ± 9.6% (mean ± 
SEM; n = 24 units; Figure 3.5.3a, blue trace). Across all animals tested, the average 
peak inhibition of single-unit activity was 60.3 ± 11.56% by intracerebral CTZ injection, 
58.9 ± 4.18% by 620-nm light, and 40.2 ± 2.7% by 525-nm green light (mean ± SEM, n = 
3 animals; Figure 3.5.3b). These effects were replicated in the awake behaving animal 
(Figure 3.5.4a). CTZ was thus able to suppress neural activity on both a cellular and 
network level in vivo and its efficacy was comparable to conventional photostimulation 




Figure 3.5.1. Cannula-electrode allows for chemical and photostimulation. (a) 
Left: photograph depicting a cannula-electrode in which a guide cannula (white 
asterisk) was glued to a 16-channel microwire array (row 1 targeting CA1, row 2 
targeting CA3) so that an optical fiber inserted through an injection cannula (white 
arrow) can be positioned 1-2 mm away from electrode tips. Scale bar: 1 mm. Right: 
Histology depicting tips of electrode tracks (asterisks) targeted to the pyramidal cell 
layer (outlined) of the dorsal hippocampus. Note robust expression of iLMO2 (green) 
in the pyramidal cells around electrode holes. DAPI stain (blue) highlights nuclei of 
migratory glial cells around electrode tips. Scale bar: 100 µm. (b) Example of single-





Figure 3.5.2. iLMO2 suppresses neural activity in vivo. (a) Population average 
(n=6) of normalized single-unit firing rate over time (middle, SEM shaded) with 
corresponding raster (top, each color corresponds to different unit) and spectrogram 
(bottom) for a representative CTZ injection trial (injected at time = 0, vertical dashed 
line). (b) Population average (n=6) of normalized single-unit firing rate, raster, and 
spectrogram for the same units shown in (a) in response to an intracerebral vehicle 





Figure 3.5.3. Average responses to CTZ and vehicle. (a) Normalized single-unit 
firing rate averaged across all intracerebral CTZ (red) and vehicle (blue) injection 
trials (n=5 trials each, same 24 units for each group) from the same animal shown in 
Figure 3.5.2. Injections occurred at t=0 denoted by vertical dashed line. (b) Average 
peak change in single-unit firing rate to light, CTZ, and vehicle across all animals 







Animal experiments. All animals were purchased from Charles River Laboratories and 
were housed in the Emory animal vivarium with a 12hr light/ 12hr dark cycle. All 
 
Figure 3.5.4. Effect of isoflurane anesthesia on iLMO activity. (a) CTZ was able to 
suppress single-unit activity in an awake rat (top) while vehicle was not (bottom). (b). 
Normalized single-unit firing rate (n = 5 units) over time for an animal on 1% 
isoflurane demonstrates a gradual increase in firing rate over time. Single-unit firing 
rate was similarly normalized to the median of a 10 minute baseline preceding an 
arbitrary “injection” time. SEM is shaded. Top: corresponding raster (each color 
corresponds to a different unit). 
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procedures were conducted in accordance to approved guidelines from the Emory 
University Institute for Animal Care and Use Committee. 
 
Stereotaxic viral injections. For animals implanted with a cannula-electrode, two month 
old male Sprague-Dawley animals (200-250 g) were anesthetized with 1.5-4% inhaled 
isoflurane and a craniectomy was made 3.3 mm posterior and 3.2 mm lateral to bregma. 
1.8 µl of AAV2/9-CAMKIIα-iLMO2 was stereotaxically injected at a depth of 3.1 mm 
ventral to pia targeting the dorsal hippocampus. Virus was injected through a glass-pulled 
pipette using a Nanoject injector (Drummond Scientific) at a rate of 275 nl/min. After 
viral injection was completed, the scalp was stapled closed and animals were allowed to 
recover for up to two weeks. 
 
In vivo electrophysiology. Animals were implanted with a cannula-electrode two weeks 
after the viral injection. We have found that two weeks is sufficient for expression of 
optogenetic vectors delivered by AAV. A guide cannula (Plastics One) was glued to a 16-
channel microwire array (Tucker Davis Technologies) so that a 0.39 NA, 200 µm core 
diameter bare fiber optic (Thorlabs) inside an injection cannula could be inserted into the 
guide cannula and positioned 1-2 mm away from the electrode tips. Four skull screws and 
one cerebellar reference screw were implanted into each animal. A craniotomy was then 
made over the dorsal hippocampus (array angled 50° from midline and centered 3.5 mm 
posterior and 2.9 mm lateral to bregma) and the cannula-electrode was manually driven 
into the brain while continuously recording to ensure ideal placement of electrodes. The 
correct stop depth was determined by identifying responsive single-units after repeated 
optical stimulation (10s continuous pulses) with green (625-nm, 2.8 mW from fiber tip) 
and orange (520-nm, 1.3 mW from fiber tip) light from externally coupled LEDs 
(Plexon). Electrophysiologic recordings were sampled at 25 kHz using our custom built 
NeuroRighter data acquisition system122. Local field potentials were bandpass filtered (1-
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500 Hz) from the raw signal and analyzed offline using custom Matlab scripts and the 
Chronux toolbox123. Single-units were detected from the bandpass filtered (500-5 kHz) 
signal and sorted offline using superparamagnetic clustering (Wave Clus) scripts  
developed by Quiroga et al124. The entire cannula-electrode was then sealed in place with 
dental acrylic (Lang Dental), the optical fiber was retracted from the guide cannula and 
replaced with a dummy cannula, and the animal was allowed to recover several days 
before further experimentation. 
 
Intracerebral injections. After the animals recovered from surgery, their 
electrophysiological responses to light, CTZ, or vehicle were investigated. The 
chronically implanted cannula-electrode allowed for multiple trials to be conducted for 
each animal, where each trial consisted of an intracerebral injection of CTZ and vehicle 
(in alternating order) on one particular day. The animals were first lightly anesthetized by 
0.5-1.5% inhaled isoflurane. Responsive units were then identified by optically 
stimulating through the guide cannula with an optical fiber coupled to a 625-nm orange 
and 520-nm green LED as described above. Only responsive units were used for 
subsequent single-unit analysis. The optical fiber was then removed from the guide 
cannula and replaced with an injection cannula connected to a Hamilton syringe 
containing either 2 µl of CTZ (600 µM) or vehicle (20 mM β-cyclodextrin in PBS). A 
baseline recording of at least 10 minutes was recorded before CTZ or vehicle was 
injected (over a period of ~5 minutes) into the brain parenchyma. After injection was 
completed, the animal was recorded under constant levels of anesthesia for up to 1 hr. 
Single-unit activity was normalized to the median firing rate 10 minutes before injection. 
Percent inhibition of spikes to CTZ was calculated by averaging the percent reduction in 
firing rate ± 1 min from the point of maximum inhibition. Percent inhibition of spikes to 
vehicle injection was calculated in the same fashion using the same time interval used in 
the analogous CTZ calculation. 
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Histology. After all experiments were completed, animals were sacrificed by 
intraperitoneal injection of Euthasol (Virbac). Animals were then transcardially perfused 
with 4% paraformaldehyde (PF). The heads of animals implanted with the cannula-
electrodes were decapitated and kept in PF at 4°C overnight to allow for visualization of 
the electrode tracks. Otherwise, the brains were dissected out and allowed to fix in PF for 
1 hr. After fixation, the brains were cryoprotected in 30% sucrose before sectioning on 
the microtome. 50 µM thickness sections were collected and mounted onto glass slides 
for imaging on an upright fluorescence microscope using NIS-elements acquisition 
software (Nikon). 
3.6 Application of iLMO2 in behaving animals 
3.6.1 Results 
 
Lastly, we tested the ability of iLMO2 to modulate motor behavior in awake behaving 
rats. Unlike conventional optogenetic stimulation, luminopsins do not require external 
light delivery and can instead be activated by systemic CTZ administration, facilitating 
long-term studies of freely behaving animals in a non-invasive manner. Unilateral lesions 
of the globus pallidus in rats have been demonstrated to produce a consistent and 
predictable increase in ipsilateral rotation after administration of stimulants such as 
amphetamine or apomorphine125. We therefore sought to mimic these motor effects with 
optogenetic inhibition of the globus pallidus with iLMO2. AAV encoding iLMO2 was 
unilaterally injected into the globus pallidus of rats, and two weeks later they underwent 
multiple amphetamine-induced rotation tests. For each test, a baseline recording of at 
least 10 minutes was first obtained before the animal was intravenously injected with 
either CTZ or vehicle through a jugular vein catheter. CTZ injections resulted in a 
significant increase in mean net ipsilateral rotations above the baseline (Figure 3.6.1, red 
 56 
trace). The effect of CTZ persisted for more than 1 hour before rotational preference 
returned back to baseline. When vehicle was injected in the same animal, such an effect 
was not observed (Figure 3.6.1, black trace).  To confirm the activation of iLMO2 upon 
CTZ administration, in vivo bioluminescence imaging was conducted in these animals 
after conclusion of the rotation experiments.  After intravenous injection of CTZ, a robust 
bioluminescence signal was detected through a craniotomy above the virus injection site 
(Figure 3.6.2a), confirming that CTZ was crossing the blood-brain-barrier and reaching 
cells expressing iLMO2. These results also demonstrate a convenient means to 
functionally detect and confirm expression of iLMOs in deep structures of the brain. To 
estimate the extent of activation of iLMO2 in the brain, acute coronal brain slices were 
prepared and imaged after bath application of CTZ. Bioluminescence was detected 
throughout the basal ganglia circuitry (Figure 3.6.2b), suggesting widespread activation 
of iLMO2. Post mortem histology confirmed that expression of iLMO2 was found 
throughout the cell bodies and projections of the globus pallidus and striatum (Figure 
3.6.3). These results demonstrate iLMO2’s ability to manipulate multiple circuits 





Figure 3.6.2. In vivo bioluminescence imaging. (a) Bioluminescence image of a rat 
expressing iLMO2 after CTZ was administered intravenously under anesthesia. (b) 
Bioluminescence image of an acute brain slice showing activation of iLMO2 
throughout the striatum and globus pallidus after addition of CTZ. Color bar indicates 
relative luminescence intensity. 
 


































Figure 3.6.1. Rotation testing. Intravenous administration of CTZ was able to 
significantly increase net ipsilateral rotations over mean baseline rate in rats 
unilaterally expressing iLMO2 in the striatum and globus pallidus. CTZ or vehicle 
was injected through a jugular venous catheter at t = 0 (dashed line). The response to 
CTZ was significantly different than vehicle by two-way ANOVA with Bonferroni 





Figure 3.6.3. Post-mortem histology. Expression of iLMO2 (green) was found 
throughout the entire striatum and globus pallidus (STR-striatum, GP-globus pallidus 
is outlined). Neurons in the globus pallidus expressed iLMO2 (bottom right) and sent 




Stereotaxic virus injections: Same as described above in section 3.5. For animals used in 
behavioral rotation tests, iLMO2 was unilaterally expressed in the striatum and globus 
pallidus of rats by two stereotaxic injections (-0.4 mm AP, ±3.5 mm ML, -5.0 mm SI; 
+1.0 mm AP, ±2.8 mm ML, -5.2 mm SI) of AAV2/9-CAMKIIα-iLMO2 as described 
above. 
Rotation tests. One week after virus injection, animals were implanted with a jugular 
venous catheter to allow for convenient intravenous injections of CTZ or vehicle during 
rotational testing. Therefore, each animal could undergo multiple trials of both CTZ and 
vehicle injections. At the start of each trial day (beginning in the mornings between 10-
12pm), animals were given amphetamine (2.5 mg/kg) by intraperitoneal injection and 
placed into a cylindrical chamber where an automated rotation counter (Columbus 
Instruments) was used to quantify both partial and full rotations. When the animals 
reached a steady baseline, they were injected with either 250 µl of CTZ (1 mg) or vehicle 
through a syringe connected to the catheter by polyethylene tubing. The number of total 
rotations per two minute intervals was then recorded for up to 1.5 hours following 
injection. 
 
In vivo bioluminescence imaging. Bioluminescence imaging was conducted after the 
conclusion of the amphetamine-induced rotation tests. A craniotomy was first performed 
over the injection sites to allow for direct visualization of the intact brain and overlaying 
dura. The animals were then deeply anesthetized with 100 mg/kg Ketamine/Xylazine and 
injected with 0.5 mg of CTZ through the jugular catheter. Bioluminescence images were 
taken using 10 - 20s exposure times in a Fuji LAS-3000 dark box equipped with a cooled 
CCD camera. The animal was subsequently sacrificed after the imaging session by 
Euthasol injection and acute brain slices were collected and imaged in a similar fashion 
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(after bath application of CTZ to reach final concentration of 30 µM) using 1-2 s 
exposure times. 
 
Histology. Same as described above in section 3.5. 
3.7 Discussion 
We report here a novel optogenetic probe that is capable of suppressing neural activity in 
response to both external light and chemical substrate. In contrast to previously described 
excitatory luminopsins that were shown to modulate neuronal excitability in vitro94, we 
have demonstrated robust inhibition of action potential firing in various scenarios in vitro 
and in vivo. First, we rationally designed inhibitory luminopsins by characterizing the 
bioluminescence emission properties of various luciferase proteins and selecting the most 
suitable ones to couple with an inhibitory opsin, NpHR. We then demonstrated that 
bioluminescence from the Renilla luciferase variant, Nano-lantern, could be used to 
activate NpHR when both are coupled together as the iLMO2 fusion protein or co-
expressed in the same cell (Figure 1). Although co-expression of opsin and luciferase 
uniquely allows for the possibility of transcellular optogenetic modulation if different 
cells are targeted, we pursued the single fusion protein approach due to its more effective 
transgene delivery and greater coupling efficiency. iLMO2 was then utilized to suppress 
single-cell action potentials and synchronous bursting activity in vitro (Figures 2 and 3). 
These effects were translated in vivo, where bimodal activation of iLMO2 was able to 
suppress single-unit firing rate and local field potential in the hippocampus of 
anesthetized rats (Figure 4). Finally, iLMO2 was used for hardware-independent 
optogenetic inhibition of the basal ganglia, where its effects increased ipsilateral rotations 
for more than an hour in awake behaving rats (Figure 5). 
 We have bypassed the challenges of delivering external light into the brain by 
making the opsin-expressing cells their own light source with the use of bioluminescent 
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proteins. The major advantage of utilizing luminopsins is that both the light source and 
opsin are genetically encoded and expressed as one molecule, which allows for 
modulating neural activity without the need for invasive hardware, as well as the ability 
to selectively target expression in a readily scalable manner. We demonstrated these 
advantages by modulating behavior in freely moving rats without the need for any 
chronically implanted devices or external light sources. Our results demonstrate that large 
structures in the brain can be targeted with luminopsins, which can be advantageous 
when multiple brain regions or diffuse circuits need to be manipulated. Indeed, 
expression of iLMO2 was found in both cell bodies and projections of the striatum and 
globus pallidus in animals used for the rotation tests, which suggests that inhibition of the 
direct pathway (striatal-nigral) and disinhibition of the indirect pathway (striato-pallido-
subthalamic-nigral) acted synergistically to modulate rotational behavior. Expression of 
iLMO2 was estimated to span a total volume greater than 20 mm3 in the brains of these 
animals, which is far greater than the predicted volume of light illumination achieved 
with a single optical fiber (the predicted spherical volume illuminated with at least 3.5 
mW/mm2, an intensity shown to reliably activate eNphR3.0126, is 1.15 mm3 using a 630-
nm, 20 mW output, 200 µm core diameter, 0.39 NA fiber127). 
 Although we were able to influence a large volume of tissue in the brain by 
delivering iLMO2 with a non-specific viral vector, one could also spatially restrict the 
expression of luminopsin to genetically defined cell populations with the use of cell-
specific promoters or transgenic animals. In addition, luciferase-derived bioluminescence 
can also be spatially localized within the cell with the use of various targeting motifs128, 
which could potentially be useful for limiting optogenetic manipulation to subcellular 
components or preventing off-target activation of surrounding opsin-expressing cells. A 
genetically encoded luminopsin can therefore achieve high spatial resolution when 
expression is carefully controlled for (e.g. with cell-specific promoters, localization 
motifs, or precise virus injections). Utilization of a genetically encoded light source can 
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also yield distinct advantages over external light sources particularly when targeting 
complex structures (e.g. cerebellum) that are problematic for efficient light 
transmission104 since the light source is directly coupled to the opsin. 
 iLMO2 was able to generate enough hyperpolarizing photocurrent to completely 
suppress neural activity in vitro, but was only able to suppress single-unit firing rate by 
60.3% on average in vivo. Our data suggests that this degree of inhibition is 
underestimated because single-unit firing rates actually increased after vehicle was 
injected. This increase in firing rate was likely not directly due to the injection itself; 
rather, baseline activity gradually increased from exposure to isoflurane anesthesia. 
Indeed, recordings from animals on low levels of isoflurane (0.5-1.5%) showed a gradual 
increase in hippocampal activity over time (Supplementary Figure 2), which agrees with 
previous findings demonstrating the excitatory effects of low dose isoflurane on 
hippocampal activity129,130. Despite this excitatory effect of isoflurane, CTZ was still able 
to suppress single-unit activity just as well as 620-nm light delivered by optical fiber. The 
challenges of delivering external light into the brain were markedly illustrated by the fact 
that luciferase-derived light actually outperformed external light of the same peak 
wavelength (525-nm) given from the same location in the brain. The utilization of 
brighter and more red-shifted luciferases may help improve the performance of iLMO2 
further, since better spectral overlap with NpHR and greater tissue penetration with 
longer wavelength light could improve both the coupling efficiency and volume of 
activation, respectively. 
 Luminopsin activity is contingent on the presence of either externally delivered 
light or luciferase substrate.  Luminopsins therefore have a wide dynamic range of 
temporal control due to two modes of activation: temporally precise activation (on the 
order of milliseconds) with external light to more gradual and longer lasting activation 
(on the order of minutes) with luciferase substrate. Luminopsin activity triggered by 
either of these modes can also be temporally tuned based on the amount of light or 
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substrate administered. The mode of activation can therefore be selected at the discretion 
of the user, where one mode can have substantial advantages or disadvantages over the 
other depending on the experimental context. For example, the gradual off-kinetics of the 
chemically activated approach can be leveraged to avoid the risk of rebound excitation 
that is exhibited by NpHR with conventional photostimulation131. Combining both modes 
of activation can create even more intricate duty cycles where external light can 
potentially add spatially and temporally precise periods of optogenetic manipulation over 
a network state primed by luciferase substrate. Since the modes of luminopsin activation 
can be both wide-acting and spatially precise, they could be appropriately utilized 
together for determining the influence of network activity (altered by luciferase substrate) 
on the activity of a particular subpopulation of neurons (altered by external light). These 
types of experiments would be more readily realized in vivo compared to other 
approaches utilizing multiple fibers or different combination of molecules132 since only 
one single molecule is needed. 
 The chemical genetic approach to light production by luminopsins is reminiscent 
of DREADD (Designer Receptors Exclusively Activated by Designer Drugs) 
technology133,134, where a physiologic actuator (G protein in the case of DREADDs, 
opsin in the case of luminopsins) is specifically activated by an otherwise biologically 
inert molecule (CNO for DREADDs, CTZ for luminopsins). Although DREADDs have 
been shown to inhibit neural activity in vitro and in vivo, they face several unique 
challenges that are not necessarily shared with the luminopsin approach. First, 
DREADDs rely on secondary endogenous signaling proteins (e.g. G proteins), which are 
not necessarily present or active in every target population of neurons. In contrast, 
everything required to manipulate neural activity is encoded in a single molecule for the 
luminopsin approach. Second, these signaling proteins are involved in a variety of 
endogenous cell signaling pathways. The downstream effects of DREADD activation can 
therefore have very diverse, unintended effects other than altering membrane 
 64 
conductance compared to opsins. Third, only a single DREADD ligand (CNO) currently 
exists, which prevents the use of different DREADDs for both excitation and inhibition in 
the same experimental paradigm. In contrast, a vast number of luciferases (each with 
their own spectral properties and substrate specificity) currently exist that can be coupled 
to compatible opsins. For example, CTZ-h specifically generates bioluminescence with 
Renilla luciferase but not Gaussia luciferase (which can only catalyze native CTZ135). 
Thus, iLMO2 can be potentially employed together with a Gaussia luciferase-based 
excitatory luminopsin (i.e. LMO1 and LMO294) without the risk of crosstalk. Fourth, 
CNO undergoes back-metabolism to clozapine in humans which has multiple targets and 
effects in the brain, which makes it prohibitive for clinical translation136. Although CTZ 
has been widely used for in vivo imaging studies in rodents, no adverse effects of CTZ or 
its metabolite have been reported. Lastly, luminopsins may not necessarily suffer the 
same degree of limited temporal control seen with other chemical genetic approaches. 
With the advent of activity-dependent luciferases (e.g. calcium dependent photoproteins 
like Aequorin137), luminopsin activity may be made responsive to neural activity in a 
closed-loop fashion and thus be activated only when it is needed. The luminopsin 
approach is thus unique in the fact that it combines the advantages of optogenetics (i.e. 
versatile and robust modulation of neural activity) with those of the DREADD approach 
(i.e. non-invasive chemical activation) into one single molecule capable of enabling 
responsive control of neural activity. 
 The luminopsin approach can be readily applied to existing and new optogenetic 
probes as they are continually developed. With the advent and discovery of new 
luciferases and opsins (each with their own different kinetics and spectral properties), 






APPLICATION OF INHIBITORY LUMINOPSINS TO EPILEPSY 
 
The previous chapters have described my efforts in developing and validating inhibitory 
luminopsins in various in vitro and in vivo models. The ability of iLMO2 to suppress 
epileptiform activity in vitro (section 3.4) as well as inhibit neural activity in limbic 
structures that are highly implicated in seizures (i.e. hippocampus, section 3.5) provides a 
just rationale to test its ability to modulate seizure activity in animal models of epilepsy. 
Although our laboratory has experience with a spontaneous seizure model in rats (via 
hippocampal tetanus toxin injection138), I have elected to test iLMO2 with acute seizure 
models to facilitate the ease of substrate administration with the timing of seizures. I have 
chosen to develop two different epilepsy models: an acute focal seizure model (via 
intracerebral bicuculline injection) to investigate the ability of iLMO2 for suppressing 
epileptiform discharges and an acute generalized seizure model (via systemic 
pentylenetetrazol) to demonstrate the scalability of the luminopsin approach. 
 
4.1 Introduction 
Epilepsy is a disorder characterized by seizures that arise spontaneously from excessive 
synchronous discharges of neurons in the brain. Choosing an appropriate seizure model is 
a constant struggle for anyone in the field, given that each model has its own advantages 
and disadvantages139. These epilepsy models can be broadly classified into acute 
(seizures that are triggered) or chronic (seizures that arise spontaneously) epilepsy 
models. Although chronic models of epilepsy generally have better face validity due to 
the fact that seizures arise spontaneously in patients with epilepsy, acute seizure models 
 66 
can provide a convenient platform for testing and screening new anti-epileptic therapies. I 
have taken the approach of utilizing multiple acute epilepsy models as a means for testing 
the efficacy of optogenetic inhibition of seizure activity with inhibitory luminopsins. 
 Acute focal blockade of inhibitory transmission has frequently been used to 
induce epileptiform discharges in animals. Bicuculline is a specific GABAA antagonist 
that has been shown to generate discharges akin to inter-ictal spikes seen in human 
patients with epilepsy. Because the mechanism of action for seizure generation is well 
known (i.e. impaired network inhibition), bicuculline has been a useful model for testing 
various anti-epileptic drugs that aim to increase inhibitory drive140–142. Optogenetic 
inhibition with halorhodopsin has also been utilized to attenuate seizure activity 
generated from focal injection of bicuculline in vivo21, which provides a good rationale 
for testing the ability of inhibitory luminopsin (which is also halorhodopsin based) to 
suppress seizure activity in this same context. 
 Pentylenetetrazol (PTZ) is another GABAergic transmission blocker that has been 
utilized for generating generalized seizures. It has been particularly useful for screening 
anti-convulsant compounds because it has been shown to be sensitive to molecules with 
varied mechanisms of action143. Although systemic administration of PTZ affects 
multiple regions in the brain, its excitatory effects are especially strong in the structures 
found in the limbic system (e.g. hippocampus, anterior thalamus). Indeed, electrical 
stimulation of certain thalamic nuclei (anterior nucleus, thalamic reticular nucleus) has 
been shown to be effective for suppressing PTZ-induced seizures144,145. The luminopsin 
approach to optogenetic inhibition is also particularly well-suited for intervening with 
PTZ-induced seizures given the fact that multiple brain structures are involved in an 
acute setting. Trying to target multiple structures with conventional optical or electrical 
means would not only be technically difficult, but also impractical for clinical translation. 
 I have chosen to target the granule cells of the dentate gyrus and the anterior 
nucleus of the thalamus with iLMO2 for testing its effectiveness in suppressing PTZ-
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induced seizures. The granule cells of the dentate gyrus appear to be a suitable target for 
optogenetic intervention because this area is highly active during PTZ-induced seizures 
as determined by c-fos immunohistochemistry146 and fMRI147. Furthermore, optogenetic 
inhibition of the dentate granule cells has been shown to prevent propagation of seizure 
activity throughout the hippocampus (i.e. the ‘dentate gate’ hypothesis of epilepsy)55. The 
anterior nucleus of the thalamus was targeted because it is the first structure activated 
after administration of PTZ147 and has also been shown to increase seizure threshold with 
high frequency electrical stimulation145. 
4.2 Optogenetic inhibition of acute focal epileptic discharges with iLMO2 
4.2.1 Results 
 
To investigate the ability of iLMO2 to modulate seizure activity, focal epileptic 
discharges were induced in the hippocampus with intracerebral injections of bicuculline 
methiodide (BM) in anesthetized rats expressing iLMO2 in the dorsal hippocampus. 
iLMO2 was first expressed in the dorsal hippocampus by stereotaxic injection of AAV 
and then chronically implanted with a cannula-electrode as described previously73. The 
chronically implanted cannula-electrode allowed for multiple injection trials to be 
conducted in the same animal. 1µl injections of 20 mM BM typically induced discharges 
within 5 minutes that increased in amplitude and frequency until plateauing around 15 
minutes and returning back to baseline after about 45 minutes (Figure 4.2.1).  
 To investigate the ability of iLMO2 in preventing BM-induced discharges, CTZ 
was administered together with bicuculline. CTZ was able to suppress the BM-induced 
discharges when it was acutely administered during the development of the discharges 
(Figure 4.2.2). Compared to vehicle, CTZ was able to significantly increase the time to 
seizure onset, decrease the seizure duration, and significantly (p < 0.05; two-tailed 
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student’s t-test; n = 5 trials each) reduce the maximum discharge frequency (Figure 
4.2.3). 
 
Figure 4.2.1. Example of bicuculline-induced discharges in the hippocampus.  
Top to bottom: Epileptic discharges (denoted by asterisks) seen in the local field 
potential increase in amplitude and frequency after injection of bicuculline. The 
single-unit firing rate and overall power (especially low frequency power, bottom) of 






Figure 4.2.2. Suppression of bicuculline-induced discharges by CTZ. (a) 
discharges induced by BM were not altered by subsequent injection of vehicle. The 
overall power and single-unit firing rate was also not significantly altered. (b) 
discharges induced by BM were reduced in frequency after subsequent injection of 
CTZ. The overall power and single-unit firing rate was also reduced after 





Stereotaxic viral injections. Two month old male Sprague-Dawley animals (200-250 g) 
were anesthetized with 1.5-4% inhaled isoflurane and a craniectomy was made 3.3 mm 
posterior and 3.2 mm lateral to bregma. 1.8 µl of AAV2/9-CAMKIIα-iLMO2 was 
stereotaxically injected at a depth of 3.1 mm ventral to pia targeting the dorsal 
hippocampus. Virus was injected through a glass-pulled pipette using a Nanoject injector 
 
Figure 4.2.3. Changes in seizure activity when CTZ or vehicle is co-administered 
with bicuculline in anesthetized rats. Administering CTZ and bicuculline together 
was able to (a) increase the time to seizure onset, (b) reduce the total seizure duration, 
and (c) reduce the maximum discharge frequency. N=5 trials each for CTZ or vehicle 
across 4 animals. Error bars indicate standard error of the mean. 
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(Drummond Scientific) at a rate of 275 nl/min. After viral injection was completed, the 
scalp was stapled closed and animals were allowed to recover for up to two weeks. 
 
In vivo electrophysiology. Animals were implanted with a cannula-electrode two weeks 
after the viral injection. We have found that two weeks is sufficient for expression of 
optogenetic vectors delivered by AAV. A guide cannula (Plastics One) was glued to a 16-
channel microwire array (Tucker Davis Technologies) so that a 0.39 NA, 200 µm core 
diameter bare fiber optic (Thorlabs) inside an injection cannula could be inserted into the 
guide cannula and positioned 1-2 mm away from the electrode tips. Four skull screws and 
one cerebellar reference screw were implanted into each animal. A craniotomy was then 
made over the dorsal hippocampus (array angled 50° from midline and centered 3.5 mm 
posterior and 2.9 mm lateral to bregma) and the cannula-electrode was manually driven 
into the brain while continuously recording to ensure ideal placement of electrodes. The 
correct stop depth was determined by identifying responsive single-units after repeated 
optical stimulation (10s continuous pulses) with green (625-nm, 2.8 mW from fiber tip) 
and orange (520-nm, 1.3 mW from fiber tip) light from externally coupled LEDs 
(Plexon). Electrophysiologic recordings were sampled at 25 kHz using our custom built 
NeuroRighter data acquisition system122. Local field potentials were bandpass filtered (1-
500 Hz) from the raw signal and analyzed offline using custom Matlab scripts and the 
Chronux toolbox123. Single-units were detected from the bandpass filtered (500-5 kHz) 
signal and sorted offline using superparamagnetic clustering (Wave Clus) scripts  
developed by Quiroga et al124. The entire cannula-electrode was then sealed in place with 
dental acrylic (Lang Dental), the optical fiber was retracted from the guide cannula and 
replaced with a dummy cannula, and the animal was allowed to recover several days 
before further experimentation. 
 
 72 
Intracerebral injections. After the animals recovered from surgery, their 
electrophysiological responses to BM with and without CTZ was investigated. The 
chronically implanted cannula-electrode allowed for multiple trials to be conducted for 
each animal, where each trial consisted of an intracerebral injection of CTZ and vehicle 
(in alternating order) on one particular day. The animals were first lightly anesthetized by 
0.5-1.5% inhaled isoflurane. An injection cannula connected to a Hamilton syringe 
containing a 1 µl mixture of either 60 µM CTZ and 2 mM BM or 2 mM BM diluted in 
vehicle (20 mM β-cyclodextrin in PBS). Each animal received either the CTZ or vehicle 
mixture in a random order. A baseline recording of at least 10 minutes was recorded 
before CTZ or vehicle was injected (over a period of ~5 minutes) into the brain 
parenchyma. After injection was completed, the animal was recorded under constant 
levels of anesthesia for up to 1 hour. 
 
Histology. After all experiments were completed, animals were sacrificed by 
intraperitoneal injection of Euthasol (Virbac). Animals were then transcardially perfused 
with 4% paraformaldehyde (PF). The heads of animals implanted with the cannula-
electrodes were decapitated and kept in PF at 4°C overnight to allow for visualization of 
the electrode tracks. Otherwise, the brains were dissected out and allowed to fix in PF for 
1 hr. After fixation, the brains were cryoprotected in 30% sucrose before sectioning on 
the microtome. 50 µM thickness sections were collected and mounted onto glass slides 




4.3 Optogenetic inhibition of acute generalized seizures with iLMO2 
4.3.1 Results 
Targeting granule cells of the dentate gyrus  
 
The ability of iLMO2 to attenuate generalized seizures was tested in rats expressing 
iLMO2 bilaterally in the dentate gyrus of the hippocampus. CTZ was administered via 
tail vein injection prior to inducing generalized seizures by systemic intraperitoneal 
injection of pentylenetetrazol (PTZ). At the doses tested, all control animals experienced 
tonic/clonic seizures (Racine level 5), while some progressed to status epilepticus and 
died. Prophylactic administration of CTZ was able to reduce the mortality associated with 
PTZ at all doses given (Figure 4.3.1a). At the 60mg/kg dose, CTZ administration was 
able to increase the latency to seizure onset and significantly (p < 0.05, one-way paired t-
test; n = 10 for each group) reduce the total seizure duration compared to vehicle control 
(Figure 4.3.1b, c). 
 All animals were sacrificed 40 minutes after the seizure onset for 
immunohistochemical analysis of c-fos expression. C-fos expression was reduced in 




Figure 4.3.1. Effects of CTZ on PTZ-induced seizures. Prophylactic administration 
of CTZ was able to (a) reduce the mortality associated with all doses of PTZ 
administered, (b) increase the latency to first twitch, and (c) reduce the total seizure 






Stereotaxic viral injections. Two month old male Sprague-Dawley animals (200-250 g) 
were anesthetized with 1.5-4% inhaled isoflurane and bilateral craniectomies were made 
4.68 mm posterior and 2.9 mm lateral to bregma. 1.8 µl of AAV2/9-CAMKIIα-iLMO2 
was stereotaxically injected at a depth of 3.2 mm ventral to pia targeting the dentate 
gyrus. Virus was injected through a glass-pulled pipette using a Nanoject injector 
(Drummond Scientific) at a rate of 275 nl/min. After viral injection was completed, the 
scalp was stapled closed and animals were allowed to recover for up to two weeks. 
 
 
Figure 4.3.2. Prophylactic treatment with CTZ reduces c-fos expression induced 
by PTZ. c-fos expression is reduced in animals that were treated with CTZ (B) 
compared to vehicle control (A). 
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Seizure induction. After animals had recovered from the viral injection surgery, they were 
habituated in a tail vein restrainer (Braintree LLC) and handled every day until the day of 
injection. On the day of injection, the lateral tail vein was visualized by soaking the tail in 
warm water. Cage-matched litter mates were randomly selected to either receive 200 µl 
of CTZ-e (1 mg total) or 200 µl of vehicle (Inject-a-lume solvent, Prolume) by tail vein 
injection. Animals were immediately returned to their home cage after injection, where 
they subsequently received an intraperitoneal injection of PTZ (60, 70, or 80 mg/kg). 
Animals were then video recorded for up to 40 minutes, where they were immediately 
sacrificed and perfused for immunohistochemical analysis. 
 
Histology. Animals were sacrificed by intraperitoneal injection of Euthasol (Virbac) 
following induction by Isoflurane. Animals were then transcardially perfused with 4% 
paraformaldehyde (PF). The brains were dissected out and allowed to fix in PF for 1 hr. 
After fixation, the brains were cryoprotected in 30% sucrose before sectioning on the 
microtome. 10 µM thickness sections were collected onto gelatin coated glass slides for 
immunohistochemistry. Sections were stained with primary c-fos antibody (Santa Cruz, 
1:100 dilution) and fluorescent secondary antibody (Alexa 594, 1:1000) before imaging 
on an upright fluorescence microscope using NIS-elements acquisition software (Nikon). 
 
Behavior analysis. Video recordings of animals were viewed by 2 blinded viewers where 
annotations about all changes in behavior were made using a modified Racine scale. 
4.4 Discussion 
iLMO2 was previously shown to inhibit neural activity in the hippocampus and in 
multiple structures of the basal ganglia73. In this study, we aimed to see whether this 
inhibitory effect could be translated to pathological states of seizure activity. Focal 
administration of bicuculline was able to induce epileptic discharges in the hippocampus 
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of rats expressing iLMO2 in the dorsal hippocampus. These discharges could be 
subsequently suppressed by focal injection of CTZ and also attenuated in their onset and 
frequency when CTZ was delivered together with bicuculline. Systemic administration of 
PTZ in animals expressing iLMO2 bilaterally in the granule cells of the dentate gyrus 
was able to induce generalized seizures that were reduced in severity in animals that 
received CTZ prophylactically. 
 These results suggest that iLMO2 can be utilized to focally suppress seizure 
activity in vivo, which agrees with previously published results using optogenetic 
inhibition to inhibit bicuculline-induced discharges21. These combined results therefore 
signify that optogenetic inhibition of principal cells in the hippocampus can attenuate 
epileptic activity that is produced from compromised inhibitory drive. PTZ also 
compromises inhibitory drive through GABA receptor antagonism, and the fact that focal 
inhibition of granule cells was able to suppress these generalized seizures suggests that 
optogenetic inhibition with iLMO2 was able to prevent/delay the spread of synchronous 
activity throughout the limbic structures that are highly involved in this model. Indeed, 
optogenetic inactivation of the granule cells of the dentate gyrus has been previously 
shown to prevent the spread of activity throughout the hippocampus and reduce the 
spontaneous seizure frequency in mice55. Prophylactic inhibition of the granule cells was 
therefore able to raise the threshold for transmitting epileptic activity throughout the 
hippocampus, providing additional evidence for the dentate gate hypothesis. 
 There are several unique advantages to the luminopsin approach to suppressing 
seizure activity compared to conventional photostimulation used in previously published 
studies. First, optogenetic inhibition was achieved in a hardware-independent fashion via 
peripheral administration of CTZ. This is of practical and translational importance 
especially when animals are undergoing tonic/clonic seizures, which can lead to damage 
or destruction of implantable hardware. Second, optogenetic inhibition could be achieved 
in a readily scalable manner. Although the expression of iLMO2 in the brain was limited 
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by focal injections of virus, multiple injections could be utilized to express iLMO2 
bilaterally in the targets of interest. This approach could easily be scaled up to include 
multiple structures (e.g. thalamus) with more injections and other methods to improve 
viral spread (e.g. convection enhanced delivery, viral vector serotype, virus injection 
parameters, etc.). Third, this approach did not lead to any rebound bursting that has been 
reported with conventional approaches of optogenetic inhibition with Halorhodopsin. 
This is most likely due to the fact that the degree of optogenetic inhibition is slowly 
tapered off as CTZ substrate was consumed or washed away, allowing time for the cell to 
return to resting membrane potential and counter any hyperpolarization current. 
 Although focal injection of bicuculline and systemic administration of PTZ do not 
necessarily reflect epileptic activity in the human, we have demonstrated that iLMO 
activity can suppress synchronous discharges in a readily scalable and hardware-
independent manner. These results therefore provide motivation to test this approach in 
other models of epilepsy that may have more construct validity to human temporal lobe 










In the previous two chapters, I have described the development and application of 
inhibitory luminopsins to epilepsy. Although manual activation of iLMO2 by 
administration of CTZ substrate was able to suppress and attenuate seizure activity, we 
aim to make this approach more effective by tying iLMO activation to seizure activity to 
achieve autonomous closed-loop suppression of seizures. In this chapter, I will describe 
my efforts in utilizing calcium-dependent luciferases for reporting neural activity and 
driving optogenetic inhibition. We call these new probes responsive luminopsins 
(rLMOs) since they are ostensibly activity-dependent. 
5.1 Introduction 
Neuromodulation that is capable of being delivered in response to a particular signal is a 
high-level goal that would bring both therapeutic advantages as well as practical 
advantages in terms of device development. Not only would these ‘closed-loop’ 
approaches make these devices more efficient in terms of power consumption (a practical 
consideration given that future implantable devices will require battery packs), but they 
would also reduce potential side effects by minimizing off-target stimulation. A good 
example of such a device that has been used for epilepsy treatment is the Responsive 
Neurostimulation System (RNS®) developed by NeuroPace (Mountain View, CA), which 
is capable of detecting the onset of seizures and automatically delivering therapeutic 
stimulation to interrupt their progression. Several groups have taken a similar approach to 
delivering optogenetic stimulation for halting seizure activity51,54,55,148. While it may be 
possible that closed-loop optogenetic stimulators could eventually be packaged into an 
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implantable device like the RNS system, optogenetic devices will face unique challenges 
of miniaturizing light sources and dealing with higher power demands. 
 Optical reporters of neural activity have undergone significant development over 
the last decade and have proven useful to visualize activity dynamics within the context 
of neural circuitry149. Although genetically encoded calcium indicators (GECIs) have 
been generally less superior than dyes in terms of sensitivity and signal strength in the 
past, significant development in recent years has made the GECIs quite comparable, if 
not better150–153. Moreover, genetically encoded bioluminescent calcium indicators also 
exist and have been utilized to image neural activity in vitro78,81,154,155 and in vivo137. It 
therefore seems appropriate to utilize these calcium-dependent luciferases to drive 
optogenetic inhibition in response to neural activity. 
5.2 Development and characterization 
5.2.1 Results 
 
I have cloned several calcium-dependent luciferases to use as potential sensors of neural 
activity and have tested them with various opsins as summarized in Table 5.1. I have 
measured calcium-dependent bioluminescence by expressing the calcium-dependent 
luciferases in HEK293 cells by transfection and stimulating them with ATP. Aequorin 
bioluminescence from transfected HEK293 cells was increased after stimulation with 
ATP (Figure 5.2.1). The bioluminescence intensity was also dependent on the CTZ 
concentration (Figure 5.2.2) and ATP concentration (Figure 5.2.3) used to stimulate the 
cells. However, when Aequorin (either with GFP or Tdt as a fluorescent tag) was co-
expressed with opsin (either Halorhodopsin or Arch) bioluminescence was significantly 
reduced (Figure 5.2.1 and Table 5.1). The presence of aggregates seen by fluorescence 
microscopy suggests that there is protein misfolding or aggregation occurring when 
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Aequorin is co-expressed with opsin. I therefore concluded that Aequorin could not be 
used together with inhibitory opsins for creation of a responsive luminopsin. 
 Next, I turned to calcium-dependent Nanolanterns as a potential candidate to use 
with inhibitory opsins. These calcium-dependent Nanolanterns are split Renilla 
luciferases that are linked by M13 and CaM calcium binding motifs. Thus when calcium 
is present, the split luciferase comes together to become functional and is able to oxidize 
CTZ to produce bioluminescence. These calcium-dependent Nanolanterns were fused to 
Halorhodopsin to create several rLMOs with different binding affinities to calcium 
(rLMO-11, rLMO-300, and rLMO-600 have KD’s of 11, 300, and 600 nM, respectively). 
When HEK293 cells expressing these rLMOs were stimulated with ATP, 
bioluminescence signal increased (Figure 5.2.4). These constructs were subsequently 
packaged into a lentiviral vector and used to transduce dissociated cortical neurons, 
which increased their bioluminescence by approximately 2-fold after stimulation with 




Table 5.1. Summary of results when various calcium-dependent luciferases were co-





Figure 5.2.1. GFP-Aequorin bioluminescence is reduced when co-expressed with 
Halorhodopsin and Arch. Top: HEK293 cells co-transfected with either GFP-
Aequorin and Archaerhodopsin (left), GFP-Aequorin and Halorhodopsin (middle), 
and GFP-Aequorin alone. Bioluminescence was imaged from these cells before 
(bottom left) and after (bottom right) addition of ATP. 
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Figure 5.2.3. ATP-dependent bioluminescence over time. Bioluminescence 
intensity from HEK293 cells expressing Aequorin (tdTA) emit bioluminescence in a 
dose-dependent fashion. 100µM ATP produced the highest bioluminescence intensity. 
 
Figure 5.2.2. Dose-dependent bioluminescence over time. Bioluminescence 
intensity from HEK293 cells expressing Aequorin (tdTA) emit bioluminescence in a 
dose-dependent fashion. The highest bioluminescence signal was seen at a 




Figure 5.2.4. Responsive luminopsins utilizing calcium-dependent Nanolantern 
increase their bioluminescence after stimulation with ATP. Fluorescence pictures 
illustrating expression of rLMO-11 (top and bottom left) and rLMO-600 (top right). 
Bottom right shows bioluminescence images of these transfected cells before and after 






Plate imager and reader assays 
Luciferase functionality was quickly assessed with a Fuji LAS-3000 gel imager (a light-
tight box equipped with a cooled CCD camera). Transfected or transduced cells were 
placed in the imager and coelenterazine (CTZ-h for Renilla, CTZ-native for Gaussia) was 
added to each well to reach a final concentration of 12µM. Luminescence images (20s 
exposure times for each image) were then taken and integrated for up to 2 minutes. 
Luminescence signals were further quantified in a luminescence plate reader (FLUOstar 
Optima, BMG Labtech). Cells were seeded and transfected in white 96-well clear-bottom 
luminescence plates (Corning) and transgene expression was confirmed by fluorescence 
microscopy the next day. Coelenterazine was then injected into the wells using a 
 
Figure 5.2.5. KCl induced bioluminescence in cortical neurons. Bioluminescence 
measurements of rLMO-11, rLMO-600, and Nanolantern alone in dissociated cortical 
neurons after stimulation with 10mM KCl (added at time = 0). 
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multichannel pipette and the plate was immediately placed into the plate reader for 
measurement of luminescence. Each sample was measured in triplicates over the 





CONCLUSION AND FUTURE DIRECTIONS 
6.1 Conclusion 
In this dissertation, I have pursued a simple question that ultimately started this incredible 
journey: “Can bioluminescence be utilized to drive light-sensitive opsins?” This question 
was motivated from a purely translational viewpoint, yet required very basic and 
fundamental science to approach the problem. 
 To answer this question, I first had to be able to measure bioluminescence. Our 
laboratory had never worked with luciferase enzymes before, so a lot of effort was spent 
on getting the right equipment and setup for detecting and imaging bioluminescence in 
vitro and in vivo (Chapter 2). The ability to measure bioluminescence was critical for me 
to be able to quantify and characterize these biological light sources so that I could pair 
them with the appropriate opsins. Achieving the ability to image bioluminescence from 
single cells was also critical to be able to concurrently measure bioluminescence along 
with intracellular recordings; these concurrent measurements allowed me to attribute the 
electrophysiological changes I was seeing to luciferase activity. 
 The next step was to develop and characterize the luminopsin constructs. A lot of 
time was spent cloning these various constructs (summarized in Appendix E), but the 
biggest challenge was learning the techniques to be able to characterize these constructs 
(e.g. whole cell patch clamp recording, in vitro extracellular recording, in vivo 
recordings). Nevertheless, these constructs were characterized in a step-wise fashion from 
single-cell recordings to animal behavior (Chapter 3). Although several iterations of 
luminopsin had to be developed, iLMO2 performed the best and was shown to be able to 
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suppress neural activity in response to both external light illumination and substrate-
induced bioluminescence in vitro and in vivo. 
 With a validated tool in hand, the next step was to apply it to animal models of 
epilepsy. Although our laboratory had an established model of chronic epilepsy (tetanus 
toxin model), I believed that it was not the best platform for testing the efficacy of 
inhibitory luminopsins due to the practical challenges of substrate delivery. I therefore 
developed two acute models of epilepsy using focal injections of bicuculline and 
systemic administration of PTZ. Although these acute models may not have the same 
construct validity with human epilepsy, they still allowed me to test the efficacy of 
iLMOs on affecting seizure activity in a predictable and controllable fashion. It was 
shown that iLMO2 was able to attenuate seizure activity induced by bicuculline, which 
demonstrates its potential as a neuromodulatory therapy and corroborates previous 
studies utilizing conventional optogenetic approaches to halt epileptic discharges in the 
hippocampus induced by bicuculline. The therapeutic potential of iLMO2 was further 
supported when it was expressed bilaterally in the granule cells of the dentate gyrus and 
shown to reduce the seizure burden from acute administration of PTZ. Given that 
systemic PTZ administration is a model for generalized seizures and affects multiple 
structures in the brain, this result demonstrated the unique scalability of the luminopsin 
approach and how it can be applied to multiple areas in the brain. 
 The overall goal of this project was to not only utilize bioluminescence as an 
alternative light source for optogenetic applications, but to also tie this bioluminescence 
to neural activity in an activity-dependent manner. In the beginning of my thesis work, I 
had focused on the development of inhibitory luminopsins as a proof-of-concept that 
bioluminescence can indeed be utilized to activate light-sensitive opsins. Chapter 5 
described my later efforts in utilizing calcium-dependent luciferases for activity-
dependent activation of light-sensitive opsins. I have been able to show that these 
activity-dependent luminopsins are able to respond to neural activity, but not yet been 
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able to demonstrate that the resulting activity-dependent bioluminescence is sufficient to 
drive optogenetic inhibition. 
6.2 Future directions 
Although iLMO2 has been shown to be effective in suppressing both normal and 
pathological neural activity, much more can be done to improve the robustness of its 
effects. For example, the coupling efficiency between the luciferase and opsin can be 
improved with the use of either brighter luciferases or more sensitive opsins. I have 
begun preliminary testing with recently described anion channelrhodopsins (e.g. 
iC1C2156, SwiChR156, GtACR1157), which have unique advantages over halorhodopsin. 
First, much larger photocurrents can be generated with these channels (on the scale of 
nano-amps) since they are more efficient at transporting ions across the membrane than 
pumps. Second, these anion channelrhodopsins offer the possibility of prolonged 
optogenetic inhibition with step function-like kinetics. Indeed, the Deisseroth lab has 
taken the same structure-guided approach to decreasing the deactivation kinetics of their 
light-activated chloride channel to create SwiChR. Utilizing an inhibitory channel with 
prolonged deactivation kinetics could be potentially useful in vivo where the frequency of 
substrate administration could therefore be minimized. 
 Much work still needs to be done regarding luciferase substrate delivery in vivo. 
We are currently limited to only acute delivery of substrate either via intravenous 
injections or intraperitoneal injections. Chronic delivery of substrate could potentially be 
achieved with implantable osmotic pumps or miniaturized drug delivery devices, but this 
approach needs to be explored in more detail (especially given the strict storage 
conditions for CTZ). Furthermore, the solubility of CTZ needs to be improved in order to 
achieve adequate concentrations in vivo without fear of utilizing too much solvent, which 
can be toxic in high doses. The commercially available solvents we use to solubilize CTZ 
for in vivo use are not ideal because they contain proprietary ingredients that could 
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potentially confound our results. I have therefore taken the approach of making my own 
solvent by complexing CTZ with beta-cyclodextrin, but more scalable approaches still 
need to be developed. With better substrate delivery methods, we could then more readily 
test inhibitory luminopsins in chronic models of epilepsy. 
 There is still more work to be done on the activity-dependent luminopsin front. 
Although progress has been made with calcium-dependent luciferases for reporting 
neural activity, there are significant challenges that still need to be addressed. First, the 
brightness of these calcium-dependent luciferases is much lower than the traditional 
luciferases. This is due to the fact that these probes usually rely on a calcium-dependent 
‘gain-of-function’ step in order to produce bioluminescence. For example, the calcium-
dependent Nanolantern luciferases are essentially split Renilla luciferases that become 
functional again only when calcium binds. This functionality is never truly the same as 
the unsplit luciferase since these conformational changes do not occur as cleanly as 
intended in situ. Thus brighter and more responsive probes need to be developed to 
achieve an adequate dynamic range to report neural activity. Second, the sensitivity of 
these luciferases to calcium needs to be made more robust. Calcium levels can fluctuate 
widely in the cell and these sensors therefore need to be appropriately calibrated to detect 
these changes. Other biological markers of activity-dependence (such as chloride, 





ILMO1 DEVELOPMENT AND CHARACTERIZATION 
 
 
In this appendix, I describe the development and testing of iLMO1, the first attempt at 
coupling bioluminescent Renilla luciferase to Halorhodopsin. These results are described 
here because the performance of iLMO1 was not as robust as iLMO2. However, this 
work provided valuable insight into construct and experimental design that was 
subsequently implemented in the development of iLMO2. 
Results 
iLMO1 consisted of a single fusion protein between Halorhodopsin and a Renilla 
luciferase BRET (bioluminescence resonance energy transfer) probe, TagRFP-Rluc107. 
TagRFP-Rluc was coupled to Halorhodopsin either as a single fusion protein or co-
expressed as separate constructs to determine which approach would yield higher 
bioluminescence-induced inhibition. Both approaches were able to hyperpolarize 
membrane potential in transfected HEK293 cells (Figure A.1). The iLMO1 fusion 
protein appeared to have a higher coupling efficiency (CTZ-induced response divided by 
lamp-induced response) compared to cells co-expressing Halorhodopsin and TagRFP-
Rluc (Figure A.2). It was therefore decided to continue characterizing iLMO1 in 
dissociated cortical neuron cultures. 
 The iLMO1 cassette was cloned into a lentiviral vector (FUGW backbone) and 
lentivirus was produced in house to transduce dissociated cortical neurons (Figure A.3). 
Intracellular recordings demonstrated that addition of CTZ during a 10s current injection 
could reduce the number of evoked action potentials (Figure A.4). On average, CTZ was 
able to reduce evoked firing rate by 63% (Figure A.5). However, this reduction in firing 
rate is most likely overestimated due to the fact that it does not take into account the 
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normal decrease in firing rate from desensitization to prolonged current injection. 
Addition to CTZ to cortical neurons expressing iLMO1 cultured on multielectrode arrays 
was also able to reduce the array-wide spontaneous firing rate (Figure A.6). I have 
subsequently utilized 1 Hz current injections to evoke activity and a perfusion system to 




Figure A.1. Characterization of HEK293 cells co-transfected with Halorhodopsin 
and TagRFP-Rluc (a) or iLMO1 fusion protein (b). Both cells bioluminescence 
when CTZ is added (dark signal denotes bioluminescence) and hyperpolarize in 
response to both green light illumination (green bar denotes period of illumination) 







Figure A.2. Coupling efficiency comparison between co-expression and fusion of 
Renilla luciferase and Halorhodopsin. Lamp-induced responses compared to CTZ-
induced responses in HEK293 cells expressing the iLMO1 fusion protein (red) or co-
expressing Halorhodopsin and TagRFP-Rluc separately (blue). iLMO1 had a higher 
coupling efficiency as indicated by the greater slope in the regression line. 
 
Figure A.3. Expression and bioluminescence of iLMO1 in cortical neurons. Left: 
dissociated cortical neurons expressing iLMO1 after lentiviral transduction. Right: 




Figure A.4. Both green lamp illumination (a) and addition of CTZ (b) was able to reduce 




Figure A.6. iLMO1 is able to suppress spontaneous bursting activity in cortical 
neurons cultured on MEAs. (a) iLMO1 expression in cortical neurons cultured on a 
multielectrode array. CTZ was able to reduce the spontaneous firing in a culture 
expressing iLMO1 (c) while having no effect in a control sister culture (b). Dotted line 
indicates when CTZ was added. Each color refers to a different culture. 
 
Figure A.5. Average change in firing rate of evoked action potentials before, 
immediately after, and 10 min after addition of CTZ to the recording chamber in 
dissociated cortical neurons expressing iLMO1. Action potentials were evoked with a 
10s, 30pA current injection. Dotted lines denote different cells. Red line denotes mean 







In this appendix, I describe my work with channelrhodopin based excitatory luminopsins. 
This work was done as part of a collaboration between Ute Hochgeschwender at Duke 
University and Ling Wei and Shan Ping Yu at Emory University using the LMO3 
construct (Gaussia luciferase and VChR1 fusion protein). In this instantiation, Gaussia 
luciferase emits blue light in the presence of CTZ to activate VChR1, an excitatory 
channelrhodopsin. 
B.1 Intracellular recordings in vitro 
To see whether LMO3 could drive excitation in response to CTZ, intracellular recordings 
were obtained in primary dissociated cortical neuron cultures expressing LMO3. LMO3 
was expressed in these cells by transduction with AAV driven by a human synapsin 
promoter. As a positive control, blue light illumination from an arc lamp was able to 
evoke action potential firing (Figure B.1.1). When CTZ was added to cells expressing 
LMO3, the rate of spontaneous action potential firing increased (Figure B.1.2b). This 
effect eventually disappeared over time as CTZ washed out and the spontaneous firing 




Figure B.1.1. Blue light illumination evokes action potential firing in cortical 
neurons expressing LMO3. Top: Blue light illumination is able to evoke action 
potential firing in cortical neurons expressing LMO3. Blue bar indicates period of 





Figure B.1.2. CTZ is able to evoke action potential firing. (a) baseline spontaneous 
firing. (b) spontaneous firing after addition of CTZ. (c) spontaneous firing 10 min 
after CTZ was washed out. 
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B.2 Extracellular recordings in vitro 
LMO3 was further tested in the context of in vitro multielectrode array recordings using 
the same methods as those described in section 3.4. Synchronous bursts were able to be 
evoked when these cultures were illuminated with blue light (Figure B.2.1). When CTZ 








Figure B.2.2. CTZ is able to evoke spikes after addition to LMO3 expressing 
neurons cultured on a multielectrode array. (a) control non-transfected culture. (b, 
c) LMO3 expressing cultures. Dotted red line indicates time CTZ was added. 
 
Figure B.2.1. Blue light is able to evoke bursts in LMO3 expressing neurons 
cultured on a multielectrode array. Top: raster plot showing spikes across 9 
electrodes of a LMO3 expressing culture that is illuminated at various times during the 
recording. Bottom: zoomed in view of a single stimulation period. Each color 
corresponds to a different electrode. Blue bar indicates period of blue light 
illumination. 
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B.3 In vivo recordings  
LMO3 was further tested in vivo, where animals expressing LMO3 were implanted with 
a cannula-electrode as described in section 3.5 The only difference is that these cannula-
electrodes were built from laminar shank-style arrays from NeuroNexus. These cannula-
electrodes still allowed recording of local field potential and single-unit activity, albiet 
with lower fidelity than the microwire arrays. When CTZ was injected through the 
cannula, single-unit firing rate increased for a period of ~10 minutes (Figure B.3.1). 
Unfortunately the recordings with this cannula-electrode were not stable enough to 
conduct the appropriate vehicle control, although it was shown that vehicle had no effect 




Figure B.3.1. CTZ is able to increase single-unit firing rate in the hippocampus of 
rats expressing LMO3. (a) Pictures of cannula-electrode used to record from CA3 
and deliver CTZ. (b) intracerebral injection of CTZ was able to increase single-unit 
firing rate. Dotted red line indicates time CTZ was injected. 
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B.4 In vivo imaging 
In vivo bioluminescence imaging was conducted in mice expressing LMO3 as described 
in section 2.3. When CTZ was delivered intranasally (150 µg in 30 µl, a bioluminescent 






Figure B.4.1. In vivo bioluminescence imaging of LMO3 in mice. CTZ delivered 
intranasally was able to generate bioluminescence above the injection site 
(somatosensory cortex). Three areas of signal intensity are seen: 1 on the nose, 2 




EXPLORING AND OPTIMIZING METHODS OF TRANSGENE 
EXPRESSION IN VITRO 
 
In this appendix, I describe the methods I have utilized and optimized for expressing 
constructs in cultured HEK293 cells and primary neuron cultures. For HEK293 cells, I 
have explored both transient transfection methods and development of stable cell lines. 
For primary dissociated cortical neuron cultures, there are several methods that are 
typically used 1.) liposomal delivery, 2.) calcium phosphate precipitation, 3.) 
electroporation or nucleofection, and 4.) viral vectors. There are advantages and 




HEK293 cells are a convenient cell line for testing expression and functionality of new 
constructs. They are easy to maintain and easy to transfect. In addition, they can also be 
patch clamped (albiet a little tricky due to the fact that they are very flat) for intracellular 
recordings. Transient transfection with lipofectamine 2000 typically yields high levels of 
expression that is detectable by fluorescence microscopy the next day (Figure C.1a). 
This approach is typically suitable for luminescence assays and intracellular recording the 
day after transfection. To prevent the need to transfect new cells every time an 
experiment is planned, I developed a stable cell line expressing iLMO1 (Figure C.1b). 
Although expression in stably expressing cell lines is typically lower than that of 
transiently transfected cells, these cells were still able to be detected by fluorescence 
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microscopy and bioluminescence imaging. These cells could therefore be utilized 
whenever they were needed without the need of an additional transfection step. 
 
Primary cortical neurons 
 
Liposomal delivery methods were explored primarily for the reasons of cost-effectiveness 
and relatively simple procedure. Expression could usually be detected by fluorescence 
microscopy the day after transfection (Figure C.2). Although expression levels were 
typically very high, there was a high level of toxicity associated with the transfection 
method as seen by altered cellular morphology and high levels of cell death. The 
transfection efficiency was also not very high (typically ~10-20%). Since lentiviral 
vectors allowed me to achieve near 100% transduction efficiency with little or no 
 
Figure C.1. Expression of iLMO1 in HEK293 cells by transient transfection or 
development of a stable cell line. (a) Transient transfection by lipofectamine yields 
high levels of expression by fluorescence miscropy (top). These cells luminesce after 
addition of CTZ (bottom). (b) A stable cell line expressing iLMO1 is able to maintain 
expression after G418 selection (top) and luminesce after addition of CTZ (bottom). 
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associated toxicity, I have primarily utilized this method of transfection for my in vitro 
studies with primary neuronal cultures. 
 
Methods 
HEK293 stable cell line development. HEK293 cells were transiently transfected using 
the same methods described in section 3.3.2. Stable cell lines were obtained in three 
ways:  
1.) Re-seeding the transiently transfected cells in media containing 1 mg/mL of 
G418 Sulfate and continuously passaging at low density in the selection media 
until the entire population of cells is stably expressing the construct (by 
visualizing fluorescent tag) 
2.) A clonal stable cell line can be achieved by re-seeding the transiently 
transfected cells down to single cell per well (by performing serial dilutions in 
a 96-well plate) in media containing 1mg/mL G418 Sulfate. Once clonal 
colonies have developed in each well, they can be continuously expanded to 
larger dishes. 
 
Figure C.2. Liposomal transfection of primary cortical neurons using 
Lipofectamine 2000 (a) or LTX reagents (b). Fluorescence images show expression 1 
day after transfection of 1 µg of pMaxGFP plasmid. 
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3.) Another alternative for achieving clonal stable cell lines is to manual pick a 
single cell from the population of transiently transfected cells and expanding it 
in selection media containing G418 sulfate. 
Liposomal transfection of primary neuron cultures. Primary neuron cultures were 
obtained using the same methods described in section 3.4.2. For lipofection, the 
manufacturer recommend protocol was utilized except with 1/10th the amount of 







TARGETED EXPRESSION OF INTERNEURONS 
 
In this appendix, I describe my efforts on developing viral vectors that have selective 
expression in GABAergic interneuron cell types. The ability to tease apart complex 
circuitry in the brain in a cell-type specific manner is what has made optogenetics such a 
powerful technique. Cell-type specific expression of opsins can be achieved in several 
ways (summarized in section 1.2). The two major approaches include utilizing cell-type 
specific promoters or the use of CRE-dependent animals.  
 At the time of this work, there were no CRE-dependent rats that could be utilized 
to target expression of opsins in GABAergic neurons. Although there were GABAergic 
specific CRE-driver mouse lines (e.g. PV-CRE, SST-CRE), we did not want to utilize 
these transgenic animals since our temporal lobe epilepsy model was in rats. We 
therefore had to turn to promoter-specific expression of opsins. The challenge with this 
approach is that these cell-type specific promoters are generally quite large (2-3 kb), and 
are thus difficult to package into a viral vector with limited cargo sizes (i.e. lentiviral 
constructs typically can only be < 9 kb, while adeno-associated viral vectors can only be 
< 4.5 kb). Fortunately, Nathanson et. al described the cell-type specificity of various 
Fugu promoters, which are much smaller in size compared to mammalian promoters, in 
the mammalian CNS159. Utilizing these much shorter fugu promoters, I generated two 
AAV constructs specific to parvalbumin and somatostatin GABAergic interneurons. 
Results 
I cloned and tested two AAV constructs: 1.) AAV-fSST-mCherry, a somatostatin specific 
AAV encoding mCherry fluorescent protein and 2.) AAV-fPV-ChR2-myc, a 
parvalbumin specific AAV encoding Channelrhodopsin. AAV-fSST-mCherry was 
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injected into the dorsal hippocampus and expression of mCherry could be seen 
throughout the pyramidal cell layer (Figure D.1a). Although these particular cell types 
were not confirmed by immunohistochemistry, the large morphology and number of cells 
suggests that they are interneurons. AAV-fPV-ChR2-myc was utilized to infect primary 
dissociated cortical neurons. A myc tag had to be utilized instead of a fluorescent protein 
to label channelrhodopsin due to cargo size limitations. Although cell-type specific 
immunohistochemistry was not performed, expression of ChR2 could be detected in these 
cells after immunocytochemistry with anti-myc antibody (Figure D.1b). More cell-type 
specific staining needs to be conducted to further validate the specificity of these vectors. 
However, at the time of this writing there are now transgenic rat CRE-driver lines for 
both parvalbumin and somatostatin cell types. This is a prime example of why you need 




Figure D.1. Testing of interneuron-specific viral vectors. (a) Expression of AAV-
fSST-mCherry in the pyramidal cell layer of the dorsal hippocampus. (b) expression 
of AAV-fPV-ChR2-myc in primary cortical neuron cultures after 







In this appendix, I list and describe the various constructs I have made over the course of 
this thesis. 
Vector Promoter Insert Description 
Opsins 
PCDNA3 CMV SwiChR2.0-EYFP Inhibitory step function 
opsin 
PCDNA3 CMV SwiChR3.0-EYFP Inhibitory step function 
opsin 
PCDNA3 CMV NpHR3.0-EYFP Inhibitory Cl- pump 
PCDNA3 CMV eArch3.0-EYFP Inhibitory H+ pump 
PCDNA3 CMV eArch3.0-linker Inhibitory H+ pump 
PCDNA3 CMV Mac-EGFP Inhibitory H+ pump 
Luciferases 
PCDNA3 CMV pTurboFP-Rluc Renilla luciferase 
PCDNA3 CMV pTagRFP-Rluc Renilla luciferase 
PCDNA3 CMV TagRFP-Rluc Renilla luciferase 
PCDNA3 CMV Nanolantern Renilla luciferase 
PCDNA3 CMV Gluc-GFP Gaussia luciferase 
PCDNA3 CMV Luc-GFP Firefly luciferase 
Luminopsins 
PCDNA3 CMV NpHR-TagRFP-Rluc iLMO1 
PCDNA3 CMV NpHR-Nanolantern iLMO2 
PCDNA3 CMV sbGluc-SwiChR2.0-EYFP Inhibitory step function 
luminopsin 
PCDNA3 CMV eArch3.0-TagRFP-Rluc  
Ca-sensitive luciferases 
PCDNA3 CMV GFP-Aequorin Ca-dependent luciferase 
PCDNA3 CMV Nanolantern-Ca(11) Ca-dependent luciferase 
PCDNA3 CMV Nanolantern-Ca(117) Ca-dependent luciferase 
PCDNA3 CMV Nanolantern-Ca(300) Ca-dependent luciferase 
PCDNA3 CMV Nanolantern-Ca(600) Ca-dependent luciferase 
rLMOs 
PCDNA3 CMV NpHR-Nanolantern-Ca(11) rLMO-11 
PCDNA3 CMV NpHR-Nanolantern-Ca(600) rLMO-600 
PCDNA3 CMV eArch3.0-linker-tdTA rLMO 
PCDNA3 CMV NpHR-tdTA rLMO 
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Vector Promoter Insert Description 
Adeno-associated viral constructs 
pAAV CAMKIIα NpHR3.0-EYFP Inhibitory Cl- pump 
pAAV fPV hChR2-mCherry Excitatory cation channel 
pAAV fPV mCherry Control vector 
pAAV CAMKIIα Mac-eGFP Inhibitory H+ pump 
pAAV CAMKIIα NpHR-Nanolantern iLMO2 
pAAV Ef1α DIO-NpHR-Nanolantern Floxed iLMO2 
pAAV fPV ChR2-myc Excitatory cation channel 
pAAV fSST ChR2-mCherry Excitatory cation channel 
pAAV fSST mCherry Control vector 
Lentiviral constructs 
pLenti Ubiq NpHR-Nanolantern iLMO2 
pLenti Ubiq NpHR-Nanolantern-Ca(11) rLMO-11 
pLenti Ubiq NpHR-Nanolantern-Ca(600) rLMO-600 
pLenti Ubiq TagRFP-Rluc Renilla luciferase 
pLenti Ubiq GFP-Aequorin Ca-dependent luciferase 
pLenti Ubiq eNano-lantern Ca-dependent luciferase 
pLenti Ubiq sbGluc-SwiChR2.0-EYFP Inhibitory step function 
luminopsin 
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